



A

PATENTS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sudhir Agrawal
Serial No.: HERewith
Filing Date: HERewith
Docket Number: CELL-050CP2
Title: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES
AND METHODS OF THEIR USE
Date: October 5, 1999

BOX PATENT APPLICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for filing in the United States Patent and Trademark office are the following documents:

- 1) Application (127 pages) with 107 pages of specification (including 7 pages of Claims and 1 page of Abstract), and 20 sheets of informal drawings consisting of Figures 1 through 18;
- 2) Small Entity Statement of Hybridon, Inc. (unexecuted);
- 3) Declaration and Power of Attorney (unexecuted); and
- 4) Return postcard.

BASIC FEE AND FEE FOR ADDITIONAL CLAIMS:

- ☐ A fee for additional claims is not required.
- ☐ A fee for additional claims is required. The additional fee has been calculated as shown below:

	NUMBER FILED		NUMBER EXTRA		RATE		FEE
TOTAL CLAIMS	-	20	=	x	9	=	
INDEPENDENT CLAIMS	-	3	=	x	39	=	
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM				+	130	=	
BASIC FILING FEE (small entity)				+	380	=	

* If less than 20, insert 20.

TOTAL

** If less than 3, insert 3.

This patent application is being submitted under 37 C.F.R. §1.53(d) and 35 U.S.C. §111, without filing the filing fee. Please be advised that the United States Patent and Trademark Office is not authorized to charge the filing fee to our Deposit Account.

Respectfully submitted,

HALE AND DORR LLP



Ann-Louise Kerner, Ph.D.

Registration No. 33,523

Attorney for Applicants

60 State Street
Boston, MA 02109
Tel. (617) 526-6000
Fax. (617) 526-5000


October 5, 1999

CERTIFICATE OF MAILING

I hereby certify that the attached papers and fees are being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Service under 37 C.F.R. 1.10 on **October 5, 1999** and is addressed to: **BOX PATENT APPLICATION**, Assistant Commissioner for Patents, Washington, D.C. 20231.

EL171838444US

"Express Mail" Label No.


Rosemarie A. Goldman

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. Hyz-050CP2)

APPLICANT OR
PATENTEE:

Sudhir Agrawal

SERIAL NO.

Pending

FILED OR
ISSUED:

HEREWITH

TITLE:

**MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES
AND METHODS OF THEIR USE**

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 C.F.R. § 1.9(f) AND § 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN:

Hybridon, Inc.

ADDRESS OF SMALL BUSINESS CONCERN:

155 Fortune Boulevard
Milford, Massachusetts 01757

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.12 and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the business concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third part or parties controls or has the power to control both.

I hereby declare that the rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled

**MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES
AND METHODS OF THEIR USE**

by the inventor, Sudhir Agrawal

☒ the specification filed herewith
☐ Application Serial No. _____, filed _____
☐ Patent No. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d), or a nonprofit organization under 37 C.F.R. § 1.9(e).

FULL NAME _____
ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing therein, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING

TITLE IN ORGANIZATION

Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757
ADDRESS OF PERSON SIGNING

Date: _____

SIGNATURE

kerner/hyz/050cp2/appln/small_ent.wpf

PATENT APPLICATION FOR
UNITED STATES LETTERS PATENT
IN THE
UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. HYZ-050CP2)

Title:

MODIFIED PROTEIN KINASE A-SPECIFIC
OLIGONUCLEOTIDES AND METHODS OF THEIR USE

Inventor:

Sudhir Agrawal

Assignee:

HYBRIDON, INC.
A Corporation of the State of Delaware

**MODIFIED PROTEIN KINASE A-SPECIFIC
OLIGONUCLEOTIDES AND METHODS OF THEIR USE**

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional continuation-in-part application claiming priority from U.S.S.N. 60/103,098, filed on October 5, 1998, and from U.S.S.N. 09/022,965, filed on February 12, 1998, which is a continuation-in-part application of U.S.S.N. 08/532,979 filed September 22, 1995.

FIELD OF THE INVENTION

The present invention relates to cancer therapy. More specifically, the present invention relates to the inhibition of the proliferation of cancer cells using modified antisense oligonucleotides complementary to nucleic acid encoding the protein kinase A RI_α subunit.

BACKGROUND OF THE INVENTION

The development of effective cancer therapies has been a major focus of biomedical research. Surgical procedures have been developed and used to treat patients whose tumors are confined to particular anatomical sites. However, at presentation, only about 25% of patients have tumors that are truly confined and amenable to surgical treatment alone (Slapak et al. in Harrison's Principles of Internal Medicine (Isselbacher et al., eds.) McGraw-Hill, Inc., NY (1994) pp. 1826-1850). Radiation therapy, like surgery, is a local modality whose usefulness in the treatment of cancer depends to a large extent

on the inherent radiosensitivity of the tumor and
its adjacent normal tissues. However, radiation
therapy is associated with both acute toxicity and
long term sequelae. Furthermore, radiation
5 therapy is known to be mutagenic, carcinogenic,
and teratogenic (Slapak et al., ibid.).

Systemic chemotherapy alone or in combination
with surgery and/or radiation therapy is currently
10 the primary treatment available for disseminated
malignancies. However, conventional
chemotherapeutic agents which either block
enzymatic pathways or randomly interact with DNA
irrespective of the cell phenotype, lack
15 specificity for killing neoplastic cells. Thus,
systemic toxicity often results from standard
cytotoxic chemotherapy. More recently, the
development of agents that block replication,
transcription, or translation in transformed
20 cells, and at the same time defeat the ability of
cells to become resistant, has been the goal of
many approaches to chemotherapy.

One strategy is to down regulate the
25 expression of a gene associated with the
neoplastic phenotype in a cell. A technique for
turning off a single activated gene is the use of
antisense oligodeoxynucleotides and their
analogues for inhibition of gene expression
30 (Zamecnik et al. (1978) *Proc. Natl. Acad. Sci. (USA)*
75:280-284). An antisense oligonucleotide
targeted at a gene involved in the neoplastic cell
growth should specifically interfere only with the
expression of that gene, resulting in arrest of

cancer cell growth. The ability to specifically block or down-regulate expression of such genes provides a powerful tool to explore the molecular basis of normal growth regulation, as well as the opportunity for therapeutic intervention (see, e.g., Cho-Chung (1993) *Curr. Opin. Thera. Patents* 3:1737-1750). The identification of genes that confer a growth advantage to neoplastic cells as well as other genes causally related to cancer and the understanding of the genetic mechanism(s) responsible for their activation makes the antisense approach to cancer treatment possible.

One such gene encodes the RI_α subunit of cyclic AMP (cAMP)-dependent protein kinase A (PKA) (Krebs (1972) *Curr. Topics Cell. Regul.* 5:99-133). Protein kinase is bound by cAMP, which is thought to have a role in the control of cell proliferation and differentiation (see, e.g., Cho-Chung (1980) *J. Cyclic Nucleotide Res.* 6:163-167). There are two types of PKA, type I (PKA-I) and type II (PKA-II), both of which share a common C subunit but each containing distinct R subunits, RI and RII, respectively (Beebe et al. in *The Enzymes: Control by Phosphorylation*, 17(A):43-111 (Academic, New York, 1986). The R subunit isoforms differ in tissue distribution (Øyen et al. (1988) *FEBS Lett.* 229:391-394; Clegg et al. (1988) *Proc. Natl. Acad. Sci. (USA)* 85:3703-3707) and in biochemical properties (Beebe et al. in *The Enzymes: Control by Phosphorylation*, 17(A):43-111 (Academic Press, NY, 1986); Cadd et al. (1990) *J. Biol. Chem.*

265:19502-19506). The two general isoforms of the R subunit also differ in their subcellular localization: RI is found throughout the cytoplasm; whereas RI localizes to nuclei, nucleoli, Golgi apparatus and the microtubule-organizing center (see, e.g., Lohmann in *Advances in Cyclic Nucleotide and Protein Phosphorylation Research*, 18:63-117 (Raven, New York, 1984; and Nigg et al. (1985) *Cell* 41:1039-1051).

An increase in the level of RI_α expression has been demonstrated in human cancer cell lines and in primary tumors, as compared with normal counterparts, in cells after transformation with the Ki-*ras* oncogene or transforming growth factor-α, and upon stimulation of cell growth with granulocyte-macrophage colony-stimulating factor (GM-CSF) or phorbol esters (Lohmann in *Advances in Cyclic Nucleotide and Protein Phosphorylation Research*, 18:63-117 (Raven, New York, 1984); and Cho-Chung (1990) *Cancer Res.* 50:7093-7100). Conversely, a decrease in the expression of RI_α has been correlated with growth inhibition induced by site-selective cAMP analogs in a broad spectrum of human cancer cell lines (Cho-Chung (1990) *Cancer Res.* 50:7093-7100). It has also been determined that the expression of RI/PKA-I and RII/PKA-II has an inverse relationship during ontogenic development and cell differentiation (Lohmann in *Advances in Cyclic Nucleotide and Protein Phosphorylation Research*, Vol. 18, 63-117 (Raven, New York, 1984); Cho-Chung (1990) *Cancer Res.* 50:7093-7100). The RI_α subunit of PKA has

thus been hypothesized to be an ontogenic growth-inducing protein whose constitutive expression disrupts normal ontogenic processes, resulting in a pathogenic outgrowth, such as malignancy

5 (Nesterova et al. (1995) *Nature Medicine* 1:528-533).

Antisense oligonucleotides directed to the RI α gene have been prepared. U.S. Patent No. 5,271,941 describes phosphodiester-linked
10 antisense oligonucleotides complementary to a region of the first 100 N-terminal amino acids of RI α which inhibit the expression of RI α in leukemia cells *in vitro*. In addition, antisense phosphorothioate oligodeoxynucleotides
15 corresponding to the N-terminal 8-13 codons of the RI α gene was found to reduced *in vivo* tumor growth in nude mice (Nesterova et al. (1995) *Nature Med.* 1:528-533).

20 Unfortunately, problems have been encountered with the use of phosphodiester-linked (PO) oligonucleotides and some phosphorothioate-linked (PS) oligonucleotides. It is known that nucleases in the serum readily degrade PO oligonucleotides.
25 Replacement of the phosphodiester internucleotide linkages with phosphorothioate internucleotide linkages has been shown to stabilize oligonucleotides in cells, cell extracts, serum, and other nuclease-containing solutions (see,
30 e.g., Bacon et al. (1990) *Biochem. Biophys. Meth.* 20:259) as well as *in vivo* (Iversen (1993) *Antisense Research and Application* (Crooke, ed) CRC Press, 461). However, some PS oligonucleotides have been found

to exhibit an immunostimulatory response, which in certain cases may be undesirable. For example, Galbraith et al. (*Antisense Res. & Dev.* (1994) 4:201-206) disclose complement activation by some PS oligonucleotides. Henry et al. (*Pharm. Res.* (1994) 11: PPDM8082) disclose that some PS oligonucleotides may potentially interfere with blood clotting.

There is, therefore, a need for modified oligonucleotides directed to cancer-related genes that retain gene expression inhibition properties while producing fewer side effects than conventional oligonucleotides.

SUMMARY OF THE INVENTION

The present invention relates to modified oligonucleotides useful for studies of gene expression and for the antisense therapeutic approach. The invention provides modified oligonucleotides that down-regulate the expression of the RI_α gene while producing fewer side effects than conventional oligonucleotides. In particular, the invention provides modified oligonucleotides that demonstrate reduced mitogenicity, reduced activation of complement and reduced antithrombotic properties, relative to conventional oligonucleotides.

It is also known that some PS oligonucleotides cause an immunostimulatory response in subjects to whom they have been

administered, which may be undesirable in some cases.

5 It is known that exclusively phosphodiester-
or exclusively phosphorothioate-linked
oligonucleotides directed to the first 100
nucleotides of the RI_α nucleic acid inhibit cell
proliferation.

10 It has now been discovered that modified
oligonucleotides complementary to the protein
kinase A RI_α subunit gene inhibit the growth of
tumors *in vivo* with at least the activity of a
comparable PO- or PS-linked oligonucleotide with
15 fewer side effects.

It has now further been discovered that
modified oligonucleotides complementary to the
protein kinase A RI_α subunit gene have a
20 synergistic growth inhibitory effect with
antibodies that bind to epidermal growth factor
receptor (EGFR) or with various classes of
cytotoxic drugs, including taxanes, platinum-
derived agents, and topoisomerase II-selective
25 drugs.

These findings have been exploited to produce
the present invention, which in a first aspect,
includes synthetic hybrid, inverted hybrid, and
30 inverted chimeric oligonucleotides and
compositions of matter for specifically down-
regulating protein kinase A subunit RI_α gene
expression with reduced side effects. Such
inhibition of gene expression is useful as an

alternative to mutant analysis for determining the biological function and role of protein kinase A-related genes in cell proliferation and tumor growth. Such inhibition of RI_α gene expression
5 can also be used to therapeutically treat diseases and disorders that are caused by the over-expression or inappropriate expression of the gene.

10 As used herein, the term "synthetic oligonucleotide" includes chemically synthesized polymers of three up to 50, preferably from about 15 to about 30, and most preferably, 18
15 ribonucleotide and/or deoxyribonucleotide monomers connected together or linked by at least one, and preferably more than one, 5' to 3' internucleotide linkage.

20 For purposes of the invention, the terms "oligonucleotide sequence that is complementary to a genomic region or an RNA molecule transcribed therefrom" and "oligonucleotide complementary to" are intended to mean an oligonucleotide that binds to the target nucleic acid sequence under
25 physiological conditions, e.g., by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other
30 means including in the case of a oligonucleotide binding to RNA, causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen base pairing under physiological conditions is measured as a

practical matter by observing interference with the function of the nucleic acid sequence.

5 In one preferred embodiment according to this aspect of the invention, the oligonucleotide is a core region hybrid oligonucleotide comprising a region of at least two deoxyribonucleotides, flanked by 5' and 3' ribonucleotide regions, each having at least four ribonucleotides. A hybrid
10 oligonucleotide having the sequence set forth in the Sequence Listing as SEQ ID NO:4 is one particular embodiment. In some embodiments, each of the 3' and 5' flanking ribonucleotide regions of an oligonucleotide of the invention
15 comprises at least four contiguous, 2'-O-substituted ribonucleotides.

For purposes of the invention, the term "2'-O-substituted" means substitution of the 2'
20 position of the pentose moiety with an -O- lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or
25 may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or with a hydroxy, an amino or a halo group, but not with a 2'-H group.

30 In some embodiments, each of the 3' and 5' flanking ribonucleotide regions of an oligonucleotide of the invention comprises at least one 2'-O-alkyl substituted ribonucleotide.

In one preferred embodiment, the 2'-O-alkyl-substituted nucleotide is a 2'-O-methyl ribonucleotide. In other preferred embodiments, the 3' and 5' flanking ribonucleotide regions of an oligonucleotide of the invention comprises at least four 2'-O-methyl ribonucleotides. In preferred embodiments, the ribonucleotides and deoxyribonucleotides of the hybrid oligonucleotide are linked by phosphorothioate internucleotide linkages. In particular embodiments, this phosphorothioate region or regions have from about four to about 18 nucleosides joined to each other by 5' to 3' phosphorothioate linkages, and preferably from about 5 to about 18 such phosphorothioate-linked nucleosides. The phosphorothioate linkages may be mixed R_p and S_p enantiomers, or they may be stereoregular or substantially stereoregular in either R_p or S_p form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

In another preferred embodiment according to this aspect of the invention, the oligonucleotide is an inverted hybrid oligonucleotide comprising a region of at least four ribonucleotides flanked by 3' and 5' deoxyribonucleotide regions of at least two deoxyribonucleotides. The structure of this oligonucleotide is "inverted" relative to traditional hybrid oligonucleotides. In some embodiments, the 2'-O-substituted RNA region has from about four to about ten 2'-O-substituted nucleosides joined to each other by 5' to 3' internucleoside linkages, and most preferably from about four to about six such 2'-O-substituted

nucleosides. In some embodiments, the oligonucleotides of the invention have a ribonucleotide region comprises at least five contiguous ribonucleotides. In one particularly preferred embodiment, the overall size of the inverted hybrid oligonucleotide is 18. In preferred embodiments, the 2'-O-substituted ribonucleosides are linked to each other through a 5' to 3' phosphorothioate, phosphorodithioate, phosphotriester, or phosphodiester linkages. The phosphorothioate 3' or 5' flanking region (or regions) has from about four to about 18 nucleosides joined to each other by 5' to 3' phosphorothioate linkages, and preferably from about 5 to about 18 such phosphorothioate-linked nucleosides. In preferred embodiments, the phosphorothioate regions will have at least 5 phosphorothioate-linked nucleosides. One specific embodiment is an oligonucleotide having substantially the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:6. In preferred embodiments of this aspect of the invention, the ribonucleotide region comprise 2'-O-substituted ribonucleotides, such as 2'-O-alkyl substituted ribonucleotides. One particularly preferred embodiment is a hybrid oligonucleotide whose ribonucleotide region comprise at least one 2'-O-methyl ribonucleotide.

30 In some embodiments, all of the nucleotides in the inverted hybrid oligonucleotide are linked by phosphorothioate internucleotide linkages. In particular embodiments, the deoxyribonucleotide flanking region or regions has from about four to

about 18 nucleosides joined to each other by 5' to 3' phosphorothioate linkages, and preferably from about 5 to about 18 such phosphorothioate-linked nucleosides. In some embodiments, the
5 deoxyribonucleotide 3' and 5' flanking regions of the hybrid oligonucleotides of the invention have about 5 phosphorothioate-linked nucleosides. The phosphorothioate linkages may be mixed R_p and S_p enantiomers, or they may be stereoregular or
10 substantially stereoregular in either R_p or S_p form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

Another embodiment is a composition of matter
15 for inhibiting the expression of protein kinase A subunit RI_α with reduced side effects, the composition comprising an inverted hybrid oligonucleotide according to the invention.

Yet another preferred embodiment according to this aspect of the invention is an inverted chimeric oligonucleotide comprising an
20 oligonucleotide nonionic region of at least four nucleotides flanked by one or more, and preferably two oligonucleotide phosphorothioate regions.
25 Such a chimeric oligonucleotide has a structure that is "inverted" relative to traditional chimeric oligonucleotides. In one particular embodiment, an inverted chimeric oligonucleotide
30 of the invention has substantially the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1. In preferred embodiments, the oligonucleotide nonionic region comprises about four to about 12 nucleotides joined to each other

by 5' to 3' nonionic linkages. In some
embodiments, the nonionic region contains
alkylphosphonate and/or phosphoramidate and/or
phosphotriester internucleoside linkages. In one
5 particular embodiment, the oligonucleotide
nonionic region comprises six nucleotides. In
some preferred embodiments, the oligonucleotide
has a nonionic region having from about six to
about eight methylphosphonate-linked nucleosides,
10 flanked on either side by phosphorothioate
regions, each having from about six to about ten
phosphorothioate-linked nucleosides. In preferred
embodiments, the flanking region or regions are
phosphorothioate nucleotides. In some
15 embodiments, the flanking region or regions have
from about four to about 24 nucleosides joined to
each other by 5' to 3' phosphorothioate linkages,
and preferably from about six to about 16 such
phosphorothioate-linked nucleosides. In preferred
20 embodiments, the phosphorothioate regions have
from about five to about 15 phosphorothioate-
linked nucleosides. The phosphorothioate linkages
may be mixed R_p and S_p enantiomers, or they may be
stereoregular or substantially stereoregular in
25 either R_p or S_p form (see Iyer et al. (1995)
Tetrahedron Asymmetry 6:1051-1054).

Another embodiment of this aspect of the
invention is a composition of matter for
30 inhibiting the expression of protein kinase A
subunit RI_α with reduced side effects, the
composition comprising an inverted chimeric
oligonucleotide according to the invention.

Another aspect of the invention is a method of inhibiting the proliferation of cancer cells *in vitro*. In this method, an oligonucleotide of the invention is administered to the cells.

5

Yet another aspect is a therapeutic composition comprising an oligonucleotide of the invention in a pharmaceutically acceptable carrier.

10

A method of treating cancer in an afflicted subject with reduced side effects is another aspect of the invention. This method comprises administering a therapeutic composition of the invention to the subject in which the protein kinase A subunit RI_α gene is being over-expressed.

15

In yet another aspect, the invention provides a method for inhibiting proliferation of cancer cells comprising:

20

(a) administering to the cells a first agent comprising a synthetic, modified oligonucleotide complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI_α, the modified oligonucleotide having from about 15 to about 30 nucleotides and being a hybrid, inverted hybrid, or inverted chimeric oligonucleotide,

25

the hybrid oligonucleotide comprising a region of at least two deoxyribonucleotides, flanked by 3' and 5' flanking ribonucleotide regions each having at least four ribonucleotides,

30

the inverted hybrid oligonucleotide comprising a region of at least four

ribonucleotides flanked by 3' and 5' flanking
deoxyribonucleotide regions of at least two
deoxyribonucleotides,

5 and the inverted chimeric oligonucleotide
comprising an oligonucleotide nonionic region of
at least four nucleotides flanked by two
oligonucleotide phosphorothioate regions; and

10 (b) administering to the cells a second
agent comprising an antibody that binds to
epidermal growth factor receptor (EGFR) or a
cytotoxic agent selected from the group consisting
of taxanes, platinum-derived agents, and
topoisomeraseII-selective drugs;

15 wherein the administering steps may be
performed simultaneously or sequentially in any
order.

In yet another aspect, the invention provides
a pharmaceutical composition comprising:

20 (a) a first agent comprising a synthetic,
modified oligonucleotide complementary to, and
capable of down-regulating the expression of,
nucleic acid encoding protein kinase A subunit
RI α , the modified oligonucleotide having from
25 about 15 to about 30 nucleotides and being a
hybrid, inverted hybrid, or inverted chimeric
oligonucleotide,

30 the hybrid oligonucleotide comprising a
region of at least two deoxyribonucleotides,
flanked by 3' and 5' flanking ribonucleotide
regions each having at least four ribonucleotides,

the inverted hybrid oligonucleotide
comprising a region of at least four
ribonucleotides flanked by 3' and 5' flanking

deoxyribonucleotide regions of at least two
deoxyribonucleotides,

and the inverted chimeric oligonucleotide
comprising an oligonucleotide nonionic region of
at least four nucleotides flanked by two
oligonucleotide phosphorothioate regions; and

(b) a second agent comprising an antibody
that binds to epidermal growth factor receptor
(EGFR) or a cytotoxic agent selected from the
group consisting of taxanes, platinum-derived
agents, and topoisomeraseII-selective drugs.

In still yet another aspect, the invention
provides a method for treating cancer in an
afflicted subject comprising:

(a) administering to the cells a first agent
comprising a synthetic, modified oligonucleotide
complementary to, and capable of down-regulating
the expression of, nucleic acid encoding protein
kinase A subunit RI α , the modified oligonucleotide
having from about 15 to about 30 nucleotides and
being a hybrid, inverted hybrid, or inverted
chimeric oligonucleotide,

the hybrid oligonucleotide comprising a
region of at least two deoxyribonucleotides,
flanked by 3' and 5' flanking ribonucleotide
regions each having at least four ribonucleotides,

the inverted hybrid oligonucleotide
comprising a region of at least four
ribonucleotides flanked by 3' and 5' flanking
deoxyribonucleotide regions of at least two
deoxyribonucleotides,

and the inverted chimeric oligonucleotide
comprising an oligonucleotide nonionic region of

at least four nucleotides flanked by two
oligonucleotide phosphorothioate regions; and

(b) administering to the cells a second
agent comprising an antibody that binds to
5 epidermal growth factor receptor (EGFR) or a
cytotoxic agent selected from the group consisting
of taxanes, platinum-derived agents, and
topoisomeraseII-selective drugs;

wherein the administering steps may be
10 performed simultaneously or sequentially in any
order.

Those skilled in the art will recognize that
15 the elements of these preferred embodiments can be
combined and the inventor does contemplate such
combination. For example, 2'-O-substituted
ribonucleotide regions may well include from one
to all nonionic internucleoside linkages.
20 Alternatively, nonionic regions may have from one
to all 2'-O-substituted ribonucleotides.
Moreover, oligonucleotides according to the
invention may contain combinations of one or more
2'-O-substituted ribonucleotide region and one or
25 more nonionic region, either or both being flanked
by phosphorothioate regions. (See *Nucleosides &
Nucleotides* 14:1031-1035 (1995) for relevant
synthetic techniques.

30

BRIEF DESCRIPTION OF THE DRAWINGS

5 The foregoing and other objects of the present invention, the various features thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which:

10 FIG. 1 is a graphic representation showing the effect of modified oligonucleotides of the invention on tumor size in a mouse relative to various controls.

15 FIG. 2 is a graphic representation showing the effect of HYB 165 with docetaxel and monoclonal antibody MAb C225 on the growth of ZR75-1 human breast cancer cells.

20 FIG. 3 is a graphic representation showing the effect of HYB 508 with docetaxel and monoclonal antibody MAb C225 on the growth of ZR75-1 human breast cancer cells.

25 FIG. 4 is a graphic representation showing the effect of HYB 165 with or without paclitaxel on the growth of geo human colon cancer cells.

30 FIG. 5 is a graphic representation showing the effect of HYB 165 and its control HYB 508 on the growth of 1A9PTX22 human ovarian cancer cells.

FIG. 6 is a graphic representation showing the effect of HYB 165 and its control HYB 508 on the growth of 1A9PTX10 human ovarian cancer cells.

5 FIG. 7 is a graphic representation showing the effect of HYB 165 and its control HYB 508 on the growth of 1A9 human ovarian cancer cells.

10 FIG. 8 is a graphic representation showing the effect of HYB 508 with or without monoclonal antibody MAb C225 on the growth of ZR75-1 human breast cancer cells.

15 FIG. 9 is a graphic representation showing the effect of HYB 165 and HYB 618 on the growth of OVCAR-3 ovarian cancer cells.

20 FIG. 10 is a graphic representation showing the effect of HYB 165 with or without docetaxel on the growth of ZR75-1 human breast cancer cells.

25 FIG. 11 is a graphic representation showing the effect of HYB 508 with or without docetaxel on the growth of ZR75-1 human breast cancer cells.

30 FIG. 12 is a graphic representation showing the effect of HYB 165 with or without monoclonal antibody MAb C225 on the growth of ZR75-1 human breast cancer cells.

FIG. 13 is a graphic representation showing the effect of HYB 165 and HYB 295 on the growth of ZR75-1 human breast cancer cells.

FIG. 14 is a graphic representation showing the effect of HYB 165 and HYB 508 on the growth of ZR75-1 human breast cancer cells.

5 FIG. 15 is a graphic representation showing the effect of HYB 165 and HYB 295 on the growth of geo colon cancer cells.

10 FIG. 16A is a graphic representation of data showing that the hybrid MBO antisense RI α inhibits tumor growth after i.p. administration.

15 FIG. 16B is a graphic representation of data showing that the hybrid MBO antisense RI α inhibits tumor growth after oral administration.

20 FIG. 17A is a graphic representation of data showing that oral hybrid MBO antisense RI α cooperatively inhibits tumor growth with taxol.

25 FIG. 17B is a graphic representation of data showing that oral hybrid MBO antisense RI α cooperatively increases survival in combination with taxol.

30 FIG. 18 is a tabular representation of histochemical analysis of GEO tumors following treatment with taxol and/or different oral MBOs. .

DESCRIPTION OF THE PREFERRED EMBODIMENT

5 The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued U.S. patents, allowed applications, published foreign applications, and references cited herein are hereby incorporated by reference.

10 Synthetic oligonucleotides of the hybrid, inverted hybrid, and inverted chimeric oligonucleotides as described above.

15 Such synthetic hybrid, inverted hybrid, and inverted chimeric oligonucleotides of the invention have a nucleotide sequence complementary to a genomic region or an RNA molecule transcribed therefore encoding the RI_α subunit of PKA. These oligonucleotides are about 15 to about 30
20 nucleotides in length, preferably about 15 to 25 nucleotides in length, but most preferably, are about 18 nucleotides long. The sequence of this gene is known. Thus, an oligonucleotide of the invention can have any nucleotide sequence
25 complementary to any region of the gene. Three non-limiting examples of an 18mer of the invention has the sequence set forth below in TABLE 1 as SEQ ID NOS:1, 4, and 6.

TABLE 1

Oligo #	Sequence (5' - 3')	Type	SEQ ID NO:
164	GCG TGC CTC CTC ACT GGC	Control	1
167	GCG <u>C</u> GC CTC CTC <u>G</u> CT GGC	Mismatched Control	2
188	G <u>C</u> A TGC <u>T</u> TC <u>C</u> AC <u>A</u> CA GGC	Mismatched Control	3
165	*** * * *** GCG UGC CTC CTC ACU GGC	Hybrid	4
168	*** * * *** GCG <u>C</u> GC CTC CTC <u>G</u> CU GGC	Mismatched Hybrid (Control)	5
166	*** ** GCG TGC CUC CUC ACT GGC	Inverted Hybrid	6
169	*** ** GCG <u>C</u> GC CUC CUC <u>G</u> CT GGC	Mismatched Inverted Hybrid (Control)	7
189	*** ** G <u>C</u> A TGC <u>A</u> UC <u>C</u> GC <u>A</u> CA GGC	Mismatched Inverted Hybrid (Control)	8
190 GCG TGC CTC CTC ACT GGC	Inverted Chimeric	1
191 GCG <u>C</u> GC CTC CTC <u>G</u> CT GGC	Mismatched Inverted Chimeric (Control)	2

X = mismatched bases

* ribonucleotide

• methylphosphonate nucleotide

Oligonucleotides having greater than 18 oligonucleotides are also contemplated by the invention. These oligonucleotides have up to 25 additional nucleotides extending from the 3', or 5' terminus, or from both the 3' and 5' termini of, for example, the 18mer with SEQ ID NOS:1, 4,

or 6, without diminishing the ability of these oligonucleotides to down regulate RI_α gene expression. Alternatively, other oligonucleotides of the invention may have fewer nucleotides than, for example, oligonucleotides having SEQ ID NOS:1, 4, or 6. Such shortened oligonucleotides maintain at least the antisense activity of the parent oligonucleotide to down-regulate the expression of the RI_α gene, or have greater activity.

The oligonucleotides of the invention can be prepared by art recognized methods. Oligonucleotides with phosphorothioate linkages can be prepared manually or by an automated synthesizer and then processed using methods well known in the field such as phosphoramidite (reviewed in Agrawal et al. (1992) *Trends Biotechnol.* **10**:152-158, *see, e.g.*, Agrawal et al. (1988) *Proc. Natl. Acad. Sci. (USA)* **85**:7079-7083) or H-phosphonate (*see, e.g.*, Froehler (1986) *Tetrahedron Lett.* **27**:5575-5578) chemistry. The synthetic methods described in Bergot et al. (*J. Chromatog.* (1992) **559**:35-42) can also be used. Examples of other chemical groups include alkylphosphonates, phosphorodithioates, alkylphosphonothioates, phosphoramidates, 2'-O-methyls, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. Oligonucleotides with these linkages can be prepared according to known methods (*see, e.g.*, Goodchild (1990) *Bioconjugate Chem.* **2**:165-187; Agrawal et al. (*Proc. Natl. Acad. Sci. (USA)* (1988) **85**:7079-7083); Uhlmann et al. (*Chem. Rev.* (1990) **90**:534-583;

and Agrawal et al. (*Trends Biotechnol.* (1992) **10**:152-158)).

5 Preferred hybrid, inverted hybrid, and
inverted chimeric oligonucleotides of the
invention may have other modifications which do
not substantially affect their ability to
specifically down-regulate RI_α gene expression.
These modifications include those which are
10 internal or are at the end(s) of the
oligonucleotide molecule and include additions to
the molecule at the internucleoside phosphate
linkages, such as cholesteryl or diamine compounds
with varying numbers of carbon residues between
15 the two amino groups, and terminal ribose,
deoxyribose and phosphate modifications which
cleave, or crosslink to the opposite chains or to
associated enzymes or other proteins which bind to
the RI_α nucleic acid. Examples of such
20 oligonucleotides include those with a modified
base and/or sugar such as arabinose instead of
ribose, or a 3', 5'-substituted oligonucleotide
having a sugar which, at one or both its 3' and 5'
positions is attached to a chemical group other
25 than a hydroxyl or phosphate group (at its 3' or
5' position). Other modified oligonucleotides are
capped with a nuclease resistance-conferring bulky
substituent at their 3' and/or 5' end(s), or have
a substitution in one or both nonbridging oxygens
30 per nucleotide. Such modifications can be at some
or all of the internucleoside linkages, as well as
at either or both ends of the oligonucleotide
and/or in the interior of the molecule (reviewed

in Agrawal et al. (1992) *Trends Biotechnol.* **10**:152-158).

5 The invention also provides therapeutic compositions suitable for treating undesirable, uncontrolled cell proliferation or cancer comprise at least one oligonucleotide in accordance with the invention, capable of specifically down-regulating expression of the RI_α gene, and a
10 pharmaceutically acceptable carrier or diluent. It is preferred that an oligonucleotide used in the therapeutic composition of the invention be complementary to at least a portion of the RI_α genomic region, gene, or RNA transcript thereof.

15 As used herein, a "pharmaceutically or physiologically acceptable carrier" includes any and all solvents (including but limited to lactose), dispersion media, coatings,
20 antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent
25 is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

30 Several preferred therapeutic composition of the invention suitable for inhibiting cell proliferation *in vitro* or *in vivo* or for treating cancer in humans in accordance with the methods of

the invention comprises about 25 to 75 mg of a lyophilized oligonucleotide(s) having SEQ ID NOS:1, 4, and/or 6 and 20-75 mg lactose, USP, which is reconstituted with sterile normal saline to the therapeutically effective dosages described herein.

In another aspect, the invention provides pharmaceutical compositions comprising a modified oligonucleotide of the invention in combination with an antibody that binds to epidermal growth factor receptor (EGFR) or a cytotoxic agent. Preferred cytotoxic agents include, without limitation, taxanes, platinum-derived agents, and topoisomeras II-selective drugs.

The invention also provides methods for treating humans suffering from disorders or diseases wherein the RI_{α} gene is incorrectly or over-expressed. Such a disorder or disease that could be treated using this method includes tumor-forming cancers such as, but not limited to, human colon carcinoma, breast carcinoma, gastric carcinoma, and neuroblastoma. In the method of the invention, a therapeutically effective amount of a composition of the invention is administered to the human. Such methods of treatment according to the invention, may be administered in conjunction with other therapeutic agents.

In certain preferred embodiments, the methods of treatment according to the invention comprise a) administering a first agent comprising a synthetic, modified oligonucleotide complementary

to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI α according to the invention; and b) administering a second agent comprising an antibody that binds to epidermal growth factor receptor (EGFR) or a cytotoxic agent selected from the group consisting of taxanes, platinum-derived agents, and topoisomeraseII-selective drugs. In some preferred embodiments according to this aspect of the invention, the two agents are administered simultaneously. In certain preferred embodiments, the second agent is administered prior to administration of the first agent.

In certain preferred embodiments, the second agent is a taxane, including but not limited to paclitaxel and docetaxel. Preferably, paclitaxel is administered in doses of up to 300 mg/m²/dose by intravenous infusion (1 hour to 24 hour duration), given at a frequency of every 21 days or less. Preferably, docetaxel is administered in doses of up to 300 mg/m²/dose by intravenous infusion (1 hour to 24 hour duration), given at a frequency of every 21 days or less.

In certain other preferred embodiments, the second agent is an antibody that binds to epidermal growth factor receptor. Preferably, the antibody is a monoclonal antibody, more preferably a humanized monoclonal antibody. In certain preferred embodiments, the monoclonal antibody is C225 (N.I. Goldstein et al., *Clin. Cancer Res.*, 1(11):1311-8 (1995). Preferably, C225 is administered in doses of up to 500 mg/m²/dose by

intravenous infusion (10 minutes to 24 hour duration), given at a frequency of every 28 days or less.

5 In preferred embodiments according to this aspect of the invention, the first agent is a synthetic modified oligonucleotide having a sequence oligonucleotide has a nucleotide sequence consisting essentially of the nucleotide sequence
10 set forth in SEQ ID NO:4. Preferably, the oligonucleotide is administer at a dose of up ot 540 mg/m²/dose by intravenous infusion (2 hours to 21 days in duration or up to 1,050 mg/m²/day by oral or rectal administration.

15 As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical formulation or method that is sufficient to show a meaningful
20 subject or patient benefit, i.e., a reduction in tumor growth or in the expression of proteins which cause or characterize the cancer. When applied to an individual active ingredient, administered alone, the term refers to that
25 ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

30 A "therapeutically effective manner" refers to a route, duration, and frequency of administration of the pharmaceutical formulation which ultimately results in meaningful patient

benefit, as described above. In some embodiments of the invention, the pharmaceutical formulation is administered via injection, sublingually, rectally, intradermally, orally, or enterally in bolus, continuous, intermittent, or continuous, followed by intermittent regimens.

The therapeutically effective amount of synthetic oligonucleotide in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of synthetic oligonucleotide with which to treat each individual patient. Initially, the attending physician will administer low doses of the synthetic oligonucleotide and observe the patient's response. Larger doses of synthetic oligonucleotide may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the dosages of the pharmaceutical compositions administered in the method of the present invention should contain about 0.1 to 5.0 mg/kg body weight per day, and preferably 0.1 to 2.0 mg/kg body weight per day. When administered systemically, the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 μ M to about 10 μ M. Preferably, the concentration of oligonucleotide at the site of aberrant gene expression should be from about 0.01

5 μM to about 10 μM , and most preferably from about
0.05 μM to about 5 μM . However, for localized
administration, much lower concentrations than
this may be effective, and much higher
10 concentrations may be tolerated. It may be
desirable to administer simultaneously or
sequentially a therapeutically effective amount of
one or more of the therapeutic compositions of the
invention when individual as a single treatment
15 episode.

20 Administration of pharmaceutical compositions
in accordance with invention or to practice the
method of the present invention can be carried out
15 in a variety of conventional ways, such as by oral
ingestion, enteral, rectal, or transdermal
administration, inhalation, sublingual
administration, or cutaneous, subcutaneous,
intramuscular, intraocular, intraperitoneal, or
20 intravenous injection, or any other route of
administration known in the art for administering
therapeutic agents.

25 When the composition is to be administered
orally, sublingually, or by any non-injectable
route, the therapeutic formulation will preferably
include a physiologically acceptable carrier, such
as an inert diluent or an assimilable edible
carrier with which the composition is
30 administered. Suitable formulations that include
pharmaceutically acceptable excipients for
introducing compounds to the bloodstream by other
than injection routes can be found in *Remington's*
Pharmaceutical Sciences (18th ed.) (Genarro, ed. (1990)

such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

10 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile. It must be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacterial and fungi. The carrier can be a solvent or dispersion medium.

15 The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents. Prolonged absorption of the injectable therapeutic agents can be brought about by the use of the compositions of agents delaying absorption. Sterile injectable solutions are prepared by incorporating the oligonucleotide in the required amount in the appropriate solvent, followed by filtered sterilization.

20 The pharmaceutical formulation can be administered in bolus, continuous, or intermittent dosages, or in a combination of continuous and intermittent dosages, as determined by the physician and the degree and/or stage of illness

of the patient. The duration of therapy using the pharmaceutical composition of the present invention will vary, depending on the unique characteristics of the oligonucleotide and the particular therapeutic effect to be achieved, the limitations inherent in the art of preparing such a therapeutic formulation for the treatment of humans, the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Compositions of the invention are useful for inhibiting or reducing the proliferation of cancer or tumor cells *in vitro*. A synthetic oligonucleotide of the invention is administered to the cells in an amount sufficient to enable the binding of the oligonucleotide to a complementary genomic region or RNA molecule transcribed therefrom encoding the RI_α subunit. In this way, expression of PKA is decreased, thus inhibiting or reducing cell proliferation.

Compositions of the invention are also useful for treating cancer or uncontrolled cell proliferation in humans. In this method, a therapeutic formulation including an antisense oligonucleotide of the invention is provided in a physiologically acceptable carrier. The individual is then treated with the therapeutic formulation in an amount sufficient to enable the

binding of the oligonucleotide to the PKA RI_α
genomic region or RNA molecule transcribed
therefrom in the infected cells. In this way, the
binding of the oligonucleotide inhibits^s or down-
5 regulates RI_α expression and hence the activity of
PKA.

In practicing the method of treatment or use
of the present invention, a therapeutically
10 effective amount of at least one or more
therapeutic compositions of the invention is
administered to a subject afflicted with a cancer.
An anticancer response showing a decrease in tumor
growth or size or a decrease in RI_α expression is
15 considered to be a positive indication of the
ability of the method and pharmaceutical
formulation to inhibit or reduce cell growth and
thus, to treat cancer in humans.

At least one therapeutic composition of the
invention may be administered in accordance with
the method of the invention either alone or in
combination with other known therapies for cancer
such as cisplatin, carboplatin, paclitaxol,
25 tamoxifen, taxol, interferon α and doxorubicin.
When co-administered with one or more other
therapies, the compositions of the invention may
be administered either simultaneously with the
other treatment(s), or sequentially. If
30 administered sequentially, the attending physician
will decide on the appropriate sequence of
administering the compositions of the invention in
combination with the other therapy.

The following examples illustrate the preferred modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results.

EXAMPLE 1

Synthesis, Deprotection, and Purification of Oligonucleotides

Oligonucleotides were synthesized using standard phosphoramidite chemistry (Beaucage (1993) *Meth. Mol. Biol.* 20:33-61) on an automated DNA synthesizer (Model 8700, Biosearch, Bedford, MA) using a beta-cyanoethyl phosphoramidate approach.

Oligonucleotide phosphorothioates were synthesized using an automated DNA synthesizer (Model 8700, Biosearch, Bedford, MA) using a beta-cyanoethyl phosphoramidate approach on a 10 micromole scale. To generate the phosphorothioate linkages, the intermediate phosphite linkage obtained after each coupling was oxidized using 3H, 1,2-benzodithiole-3H-one-1,1-dioxide (see Beaucage, in *Protocols for Oligonucleotides and Analogs: Synthesis and Properties*, Agrawal (ed.), (1993) Humana Press, Totowa, NJ, pp. 33-62). Similar synthesis was carried out to generate phosphodiester linkages, except that a standard oxidation was carried out using standard iodine reagent. Synthesis of inverted chimeric oligonucleotide was carried out in the same manner, except that methylphosphonate linkages were assembled using nucleoside methylphosphonamidite (Glen Research, Sterling,

56303 449440
VA), followed by oxidation with 0.1 M iodine in tetrahydrofuran/2,6-lutidine/water (75:25:0.25) (see Agrawal & Goodchild (1987) *Tet. Lett.* **28**:3539-3542). Hybrids and inverted hybrid
5 oligonucleotides were synthesized similarly, except that the segment containing 2'-O-methylribonucleotides was assembled using 2'-O-methylribonucleoside phosphoramidite, followed by
10 oxidation to a phosphorothioate or phosphodiester linkage as described above. Deprotection and purification of oligonucleotides was carried out according to standard procedures, (see Padmapriya et al. (1994) *Antisense Res. & Dev.* **4**:185-199), except
15 for oligonucleotides containing methylphosphonate-containing regions. For those oligonucleotides, the CPG-bound oligonucleotide was treated with concentrated ammonium hydroxide for 1 hour at room temperature, and the supernatant was removed and
20 evaporated to obtain a pale yellow residue, which was then treated with a mixture of ethylenediamine/ethanol (1:1 v/v) for 6 hours at room temperature and dried again under reduced pressure.

25 **EXAMPLE 2**

Propagation and Quantitation of Cell Lines and Virus Stocks

30 The cell line utilized was the CEM-SS cell line (Southern Research Institute-Frederick Research Center, Frederick, MD). These cells are highly susceptible to infection with HIV, rapidly form multinucleated syncytia, and are eventually killed by HIV. The cells were maintained (2-7 x

10⁵ cells per ml) in RPMI 1640 tissue culture medium supplemented with 10% fetal bovine serum, glutamine, and antibiotics, and were passaged twice weekly at 1:20 dilution. Passage number was
5 logged each week. Cells were discarded after twenty weeks of passage and fresh CEM-SS cells thawed and utilized in the assay. Stocks of CEM-SS cells were frozen in liquid nitrogen in 1 ml NUNC vials in 90% fetal calf serum and 10%
10 dimethyl sulfoxide (DMSO). Following thawing, CEM-SS cells were routinely ready to be utilized in the primary screen assay after two weeks in culture. Prior to replacing a late passage cell line, the new CEM-SS cells were tested in the
15 screening assay protocol utilizing the current stock of infectious virus and AZT. If the infectivity of the virus was significantly different on the new cells or if AZT appeared less active than expected the new cells were not
20 entered into the screening program. Mycoplasma testing was routinely performed on all cell lines.

Virus utilized Southern Research Institute-Frederick Research Center. Virus pools were
25 prepared and titrated in CEM-SS cells, placed in 5 ml aliquots, and frozen at -135°C. After thawing, unused virus is discarded to avoid changes in infectious titer. Virus pools were prepared by the acute infection of 5×10^5 CEM-SS cells with
30 HIV in a volume of 200 μ l at a multiplicity of infection determined to give complete cell killing at day 7 post-infection (approximately 0.05 for the III_B isolate of HIV-1 and 0.01 for the RF isolate of HIV-1). Infection was allowed to

5 proceed for one hour at 37°C, after which the
cells were transferred to a T25 flask and the
volume increased to 2 ml. On day 1 post-infection
the volume was brought to 5 ml and on day 2 the
10 volume was increased to 10 ml. Beginning on day
4, the cells were pelleted, the supernatant saved,
and the cells resuspended in a fresh 10 ml aliquot
of tissue culture medium. Complete medium changes
on a daily basis, rather than allowing growth of
the cells in the medium for longer periods of
time, allowed the virus inoculum utilized in the
primary screen to remain relatively undepleted of
nutrients when it is used to infect cells. The
staining reaction utilized (XTT, see method below)
15 required that the glucose concentration remain
high (161). Wells depleted of glucose by cell
growth will not permit metabolic conversion of the
tetrazolium dye to the formazan product.

20 Cell-free supernatants from the acutely
infected cells were saved on day 4, day 5, day 6,
and day 7. An aliquot of supernatant was saved
separately on each day for use in titer
determination. Titer determinations included
25 reverse transcriptase activity assay (see below),
endpoint titration or plaque assay (CEM-SS)
quantification of infectious particles (see
below), and quantification of cell killing
kinetics.

30 It has been determined that peak levels of
infectious virus are produced in the acutely
infected cultures as the viability of the cells
falls through the 50% level. Since the primary

required to kill all of the CEM-SS cells in each well and this minimum amount of virus was utilized for performance of all primary testing.

5 Cell Preparation:

CEM-SS cells (or other established human cell line used in these experiments) were passaged in T-150 flasks for use in the assay. On the day preceding the assay, the cells were split 1:2 to assure they would be in an exponential growth phase at time of infection. On the day of assay the cells were washed twice with tissue culture medium and resuspended in fresh tissue culture medium. Total cell and viability counting was performed using a hemacytometer and trypan blue dye exclusion. Cell viability was greater than 95% for the cells to be utilized in the assay. The cells were pelleted and resuspended at 2.5×10^4 cells per ml in tissue culture medium. Cells were added to the drug-containing plates in a volume of 50 μ l.

Virus Preparation:

25 A pretitered aliquot of virus was removed from the freezer (-80°C) and allowed to thaw slowly to room temperature in a biological safety cabinet. The virus was resuspended and diluted into tissue culture medium such that the amount of virus added to each well in a volume of 50 μ l will be the amount determined to give complete cell killing at 6 days post-infection. In general the virus pools produced with the IIIB isolate of HIV required the addition of 5 μ l of virus per well. Pools of RF

virus were five to ten-fold more potent, requiring
0.5-1 μ l per well. TCID₅₀ calculation by endpoint
titration in CEM-SS cells indicated that the
multiplicity of infection of these assays ranged
5 from 0.005-2.5.

Plate Format:

Each plate contained cell control wells (cells
10 only), virus control wells (cells plus virus),
drug toxicity control wells (cells plus drug
only), drug colorimetric control wells (drug only)
as well as experimental wells (drug plus cells
plus virus).

15 XTT Staining of Screening Plates:

After 6 days of incubation at 37°C in a 5% CO₂
incubator the test plates were analyzed by
20 staining with the tetrazolium dye XTT. XTT-
tetrazolium is metabolized by the mitochondrial
enzymes of metabolically active cells to a soluble
formazan product, allowing the rapid quantitative
analysis of the inhibition of HIV-induced cell
25 killing by anti-HIV test substances. On day 6
post-infection plates were removed from the
incubator and observed. The use of round bottom
microtiter plates allows rapid macroscopic
analysis of the activity of a given test compound
30 by the evaluation of pellet size. The results of
the macroscopic observations were confirmed and
enhanced by further microscopic analysis.

XTT solution was prepared daily as a stock of 1 mg/ml in PBS. Phenazine methosulfate (PMS) solution was prepared at 15 mg/ml in PBS and stored in the dark at -20°C. XTT/PMS stock was prepared immediately before use by diluting the PMS 1:100 into PBS and adding 40 μ l per ml of XTT solution. Fifty microliters of XTT/PMS was added to each well of the plate and the plate was incubated for an additional 4 hours at 37°C. Adhesive plate sealers were used in place of the lids, the sealed plate was inverted several times to mix the soluble formazan product and the plate was read spectrophotometrically at 450 nm with a Molecular Devices Vmax plate reader. Using an in-house computer program %CPE Reduction, %Cell Viability, $IC_{25, 50 \text{ \& } 95}$, $TC_{25, 50 \text{ \& } 95}$ and other indices were calculated and the graphic results summary was displayed.

20 b. Reverse Transcriptase Activity Assay:

A microtiter based reverse transcriptase (RT) reaction was utilized (Buckheit et al (1991) *AIDS Research and Human Retroviruses* 7:295-302). Tritiated thymidine triphosphate (NEN) (TTP) was resuspended in distilled H₂O at 5 Ci/ml. Poly rA and oligo dT were prepared as a stock solution which was kept at -20°C. The RT reaction buffer was prepared fresh on a daily basis and consists of 125 μ l 1M EGTA, 125 μ l dH₂O, 125 μ l Triton X-100, 50 μ l 1M Tris(pH 7.4), 50 μ l 1M DTT, and 40 μ l 1M MgCl₂. These three solutions were mixed together in a ratio of 1 parts distilled water. Ten microliters of this reaction mixture was

placed in a round bottom microtiter plate and 15
μl of virus containing supernatant was added and
mixed. The plate was incubated at 37°C and
incubated for 60 minutes. Following reaction, the
5 reaction volume was spotted onto filter mats,
washed 6 times for 5 minutes each in a 5% sodium
phosphate buffer, 2 times for 1 minute each in
distilled water, 2 times for 1 minute each in 70%
ethanol, and then dried. The dried filter mat was
10 placed in a plastic sample bag, Betaplate
scintillation fluid was added and the bag was
heat-sealed. Incorporated radioactivity was
quantified utilizing a Wallac Microbeta
scintillation counter.

15 c. p24 ELISA:

ELISA kits were purchased from Coulter. The assay
is performed according to the manufacturer's
20 recommendations. Prior to ELISA analysis we
routinely performed the reverse transcriptase
activity assays (described above) and used the
values for incorporated radioactivity in the RT
activity assay to determine the dilution of our
25 samples requires for the ELISA. We have
constructed standard curves so that the dilutions
of virus to be used in the p24 ELISA can be
accurately determined from the RT activity assay.
Control curves are generated in each assay to
30 accurately quantify the amount of capsid protein
in each sample. Data was obtained by
spectrophotometric analysis at 450 nm using a
Molecular Devices Vmax plate reader. P24
concentrations were calculated from the optical

density values by use of the Molecular Devices software package Soft Max.

d. Infectious Particles:

5 Infectious virus particles were qualified
utilizing the CEM-SS plaque assay as described by
Nara, P.L. and Fischinger, P.J. (1988)
Quantitative infectivity assay for HIV-1 and HIV-2
10 *Nature* 332:469-470). Flat bottom 96-well
microtiter plates (Costar) were coated with 50 μ l
of poly-L-lysine (Sigma) at 50 μ g/ml for 2 hours
at 37°C. The wells were then washed with PBS and
2.5 x 10⁵ CEM-SS cells were placed in the
15 microtiter well where they became fixed to the
bottom of the plate. Enough cells were added to
form a monolayer of CEM-SS cells in each well.
Virus containing supernatant was added from each
well of the XTT plate, including virus and cell
20 controls and each serial dilution of the test
substance. The number of syncytia were qualified
in the flat-bottom 96-well microtiter plate with
an Olympus CK2 inverted microscope at 4 days
following infection. Each syncytium resulted from
25 a single infectious HIV virion.

Anti-HIV Activity in Fresh Human Cells: Assay in
Fresh Human T-Lymphocytes

30 Fresh human peripheral blood lymphocytes (PBL) are
isolated from voluntary Red Cross donors,
seronegative for HIV and HBV. Leukophoresed blood
is diluted 1:1 with Dulbecco's phosphate buffered
saline (PBS), layered over 14 mL of Ficoll-Hypaque

density gradient in a 50 mL centrifuge tube. Tubes are then centrifuged for 30 minutes at 600 X g. Banded PBLs are gently aspirated from the resulting interface and subsequently washed 2X
5 with PBS by low speed centrifugation. After final wash, cells are enumerated by trypan blue exclusion and re-suspended at 1×10^7 /mL in RPMI 1640 with 15% Fetal Bovine Serum (FBS), 2 mM L-glutamine, 4 mg/mL PHA-P and allowed to incubate
10 for 48 - 72 hours at 37°C. After incubation, PBLs are centrifuged and reset in RPMI 1640 with 15% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μ g/mL streptomycin, 10 μ g/mL gentamycin, and 20 U/mL recombinant human IL-2. PBLs are maintained
15 in this medium at a concentration of $1-2 \times 10^6$ /mL with bi-weekly medium changes, until use in assay protocol.

For the PBL assay, PHA-P stimulated cells from at
20 least two normal donors are pooled, set in fresh medium at 2×10^6 /mL and plated in the interior wells of a 96 well round bottom microplate at 50 μ L/well. Test drug dilutions are prepared at a 2X concentration in microtiter tubes and 100 μ L of
25 each concentration is placed in appropriate wells in a standard format. Fifty microliters of a predetermined dilution of virus stock is placed in each test well. Wells with cells and virus alone are used for virus control. Separate plates are
30 identically set without virus for drug cytotoxicity studies using an XTT assay system.

In the standard PBL assay (MOI: 0.2), the assay was ended on day 7 following collection of cell

free supernatant samples for reverse transcriptase activity assay. In the low MOI PBL assay (MOI: 0.02), supernatant samples were collected on day 6, day 11, and day 14 post-infection and analyzed for RT activity. Tritiated thymidine triphosphate (NEN) (TTP) was resuspended in distilled H₂O at 5 Ci/ml. Poly rA and oligo dT were prepared as a stock solution which was kept at -20°C. The RT reaction buffer was prepared fresh on a daily basis and consists of 125 μ l 1M DTT, and 40 μ l 1M MgCl₂. These three solutions were mixed together in a ratio of 2 parts TTP, 1 part poly rA:oligo dT, and 1 part reaction buffer. Ten microliters of this reaction mixture was placed in a round bottom microtiter plate and 15 μ l of virus containing supernatant was added and mixed. The plate was incubated at 37°C in a water bath with a solid support to prevent submersion of the plate and incubated for 60 minutes. Following reaction, the reaction volume was spotted onto pieces of DE81 paper, washed 5 times for 5 minutes each in a 5% sodium phosphate buffer, 2 times for 1 minute each in distilled water, 2 times for 1 minute each in 70% ethanol, and then dried. Opti-Fluor O was added to each sample and incorporated radioactivity was quantified utilizing a Wallac 1450 Microbetaplus liquid scintillation counter.

Tritiated thymidine incorporation was measured in parallel cultures at day 7. Each well was pulsed with 1 μ Ci of tritiated thymidine and the cells were harvested 18 hours later with a Skatron cell harvester onto glass fiber filter papers. The filters were dried, placed in a scintillation vial

with 1 ml of scintillation cocktail and incorporated radioactivity was quantified on a Packard Tri-Carb 1900 TR liquid scintillation counter.

5

Anti-HIV Activity in Fresh Human Cells:
Assay in Fresh Human Monocyte-Macrophages

10 For isolation of adherent cells, 3×10^6 non-PHA
stimulated peripheral blood cells were resuspended
in Hanks buffered saline (with calcium and
magnesium) supplemented with 10% human AB serum.
The cells were placed in a 24-well microtiter
15 plate at 37°C for 2 hours. Non-adherent cells
were removed by vigorously washing six times. The
adherent cells were cultured for 7 days in RPMI
1640 tissue culture medium with 15% fetal bovine
serum. The cultures were carefully monitored for
20 confluency during this incubation period.
Infection of the cells was performed with the
monocytotropic HIV-1 strains BaL or ADA and the
matched pair of AZT-sensitive and AZT-resistant
virus isolates. Each of these virus isolates was
25 obtained from the NIAID AIDS Research and
Reference Reagent Program. High titer pools of
each of these viruses have been harvested from
infected cultures of peripheral blood adherent
cells and frozen in 1.0 ml aliquots at -80°C.
30 Monocyte-macrophage monolayers were infected at an
MOI of 0.1. Compounds to be evaluated in the
monocyte-macrophage assay are added to the
monolayers shortly before infection in order to

maximize the potential for identifying active compounds.

5 At 2 days post-infection, the medium was decanted
and the cultures washed twice with complete medium
in order to remove excess virus. Fresh medium
alone or medium containing the appropriate
concentrations of drugs was added and incubation
continued for an additional 5 days. XTT-
10 tetrazolium or trypan blue exclusion assays (for
cell viability) and HIV p24 ELISA assays (for
production of p24 core antigen) were performed on
Day 7 post-infection. ELISA kits were purchased
from Coulter. The assay is performed according to
15 the manufacturer's recommendations. Control
curves are generated in each assay to accurately
quantify the amount of capsid protein in each
sample. Data was obtained by spectrophotometric
analysis at 450 nm using a Molecular Devices Vmax
20 plate reader. P24 concentrations were calculated
from the optical density values by use of the
Molecular Device software package Soft Max.

25

[-----
----- To determine the relative effect of
inverted hybrid or inverted chimeric structure on
30 oligonucleotide-mediated depletion of complement,
the following experiments were performed. Venous
blood was collected from healthy adult human
volunteers. Serum was prepared for hemolytic
complement assay by collecting blood into

vacutainers (Becton Dickinson #6430 Franklin Lakes, NJ) without commercial additives. Blood was allowed to clot at room temperature for 30 minutes, chilled on ice for 15 minutes, then

5 centrifuged at 4°C to separate serum. Harvested serum was kept on ice for same day assay or, alternatively, stored at -70°C. Buffer, or an oligonucleotide sample was then incubated with the serum. The oligonucleotides tested were 25mer

10 oligonucleotide phosphodiesterases or phosphorothioates, 25mer hybrid oligonucleotides, 25mer inverted hybrid oligonucleotides, 25mer chimeric oligonucleotides, and 25mer inverted chimeric oligonucleotides. Representative hybrid

15 oligonucleotides were composed of seven to 13 2-O-methyl ribonucleotides flanked by two regions of six to nine deoxyribonucleotides each. Representative 25mer inverted hybrid oligonucleotides were composed of 17

20 deoxyribonucleotides flanked by two regions of four ribonucleotides each. Representative 25mer chimeric oligonucleotides were composed of six methylphosphonate deoxyribonucleotides and 19 phosphorothioate deoxyribonucleotides.

25 Representative inverted chimeric oligonucleotides were composed of from 16 to 17 phosphorothioate deoxyribonucleotides flanked by regions of from two to seven methylphosphonate

30 deoxyribonucleotides, or from six to eight methylphosphonate deoxyribonucleotides flanked by nine to ten phosphorothioate deoxyribonucleotides, or two phosphorothioate regions ranging from two to 12 oligonucleotides, flanked by three phosphorothioate regions ranging in size from two

to six nucleotides in length. A standard CH50
assay (See Kabat and Mayer (eds), *Experimental*
Immunochemistry, 2d Ed., Springfield, IL, CC Thomas,
p. 125) for complement-mediated lysis of sheep red
5 blood cells (Colorado Serum Co.) sensitized with
anti-sheep red blood cell antibody (hemolysin,
Diamedix, Miami, FL) was performed, using
duplicate determinations of at least five
dilutions of each test serum, then hemoglobin
10 release into cell-free supernates was measured
spectrophotometrically at 541 nm.

EXAMPLE 3

In Vitro Mitogenicity Studies

15 To determine the relative effect of inverted
hybrid or inverted chimeric structure on
oligonucleotide-mediated mitogenicity, the
following experiments were performed. Spleen was
20 taken from a male CD1 mouse (4-5 weeks, 20-22 g;
Charles River, Wilmington, MA). Single cell
suspensions were prepared by gently mincing with
frosted edges of glass slides. Cells were then
cultured in RPMI complete media (RPMI media
25 supplemented with 10% fetal bovine serum (FBS), 50
micromolar 2-mercaptoethanol (2-ME), 100 U/ml
penicillin, 100 micrograms/ml streptomycin, 2 mM
L-glutamine). To minimize oligonucleotide
degradation, FBS was first heated for 30 minutes
30 at 65°C (phosphodiester-containing
oligonucleotides) or 56°C (all other
oligonucleotides). Cells were plated in 96 well
dishes at 100,000 cells per well (volume of 100
microliters/well). One type of each

oligonucleotide described in Example 2 above in 10 microliters TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) was added to each well. After 44 hours of culturing at 37°C, one microcurie tritiated
5 thymidine (Amersham, Arlington Heights, IL) was added in 20 microliters RPMI media for a 4 hour pulse labelling. The cells were then harvested in an automatic cell harvester (Skatron, Sterling, VA) and the filters were assessed using a
10 scintillation counter. In control experiments for mitogenicity, cells were treated identically, except that either media (negative control) or concanavalin A (positive control) was added to the cells in place of the oligonucleotides.

15 All of the inverted hybrid oligonucleotides proved to be less immunogenic than phosphorothioate oligonucleotides. Inverted hybrid oligonucleotides having phosphodiester
20 linkages in the 2'-O-methyl region appeared to be slightly less immunogenic than those containing phosphorothioate linkages in that region. No significant difference in mitogenicity was observed when the 2'-O-methyl ribonucleotide
25 region was pared down from 13 to 11 or to 9 nucleotides. Inverted chimeric oligonucleotides were also generally less mitogenic than phosphorothioate oligonucleotides. In addition, these oligonucleotides appeared to be less
30 mitogenic than traditional chimeric oligonucleotides, at least in cases in which the traditional chimeric oligonucleotides had significant numbers of methylphosphonate linkages near the 3' end. Increasing the number of

methyolphosphonate linkers in the middle of the oligonucleotide from 5 to 6 or 7 did not appear to have a significant effect on mitogenicity. These results indicate that incorporation of inverted hybrid or inverted chimeric structure into an oligonucleotide can reduce its mitogenicity.

EXAMPLE 4

In Vitro Studies

10

To determine the relative effect of inverted hybrid or inverted chimeric structure on oligonucleotide-induced mitogenicity, the following experiments were performed. Venous blood was collected from healthy adult human volunteers. Plasma for clotting time assay was prepared by collecting blood into siliconized vacutainers with sodium citrate (Becton Dickinson #367705), followed by two centrifugations at 4°C to prepare platelet-poor plasma. Plasma aliquots were kept on ice, spiked with various test oligonucleotides described in Example 2 above, and either tested immediately or quickly frozen on dry ice for subsequent storage at -20°C prior to coagulation assay. Activated partial thromboplastin time (aPTT) was performed in duplicate on an Electra 1000C (Medical Laboratory Automation, Mount Vernon, NY) according to the manufacturer's recommended procedures, using Actin FSL (Baxter Dade, Miami, FL) and calcium to initiate clot formation, which was measured photometrically. Prolongation of aPTT was taken as an indication of clotting inhibition side effect produced by the oligonucleotide.

Traditional phosphorothioate oligonucleotides produced the greatest prolongation of aPTT, of all of the oligonucleotides tested. Traditional hybrid oligonucleotides produced somewhat reduced prolongation of aPTT. In comparison with traditional phosphorothioate or traditional hybrid oligonucleotides, all of the inverted hybrid oligonucleotides tested produced significantly reduced prolongation of aPTT. Inverted hybrid oligonucleotides having phosphodiester linkages in the 2'-O-substituted ribonucleotide region had the greatest reduction in this side effect, with one such oligonucleotide having a 2'-O-methyl RNA phosphodiester region of 13 nucleotides showing very little prolongation of aPTT, even at oligonucleotide concentrations as high as 100 micrograms/ml. Traditional chimeric oligonucleotides produce much less prolongation of aPTT than do traditional phosphorothioate oligonucleotides. Generally, inverted chimeric oligonucleotides retain this characteristic. At least one inverted chimeric oligonucleotide, having a methylphosphonate region of seven nucleotides flanked by phosphorothioate regions of nine nucleotides, gave better results in this assay than the traditional chimeric oligonucleotides at all but the highest oligonucleotide concentrations tested. These results indicate that inverted hybrid and inverted chimeric oligonucleotides may provide advantages in reducing the side effect of clotting inhibition when they are administered to modulate gene expression *in vivo*.

EXAMPLE 5

In Vivo Complement Activation Studies

5 Rhesus monkeys (4-9 kg body weight) are
acclimatized to laboratory conditions for at least
7 days prior to the study. On the day of the
study, each animal is lightly sedated with
ketamine-HCl (10 mg/kg) and diazepam (0.5 mg/kg).
Surgical level anesthesia is induced and
10 maintained by continuous ketamine intravenous drip
throughout the procedure. The oligonucleotides
described in Example 2 above are dissolved in
normal saline and infused intravenously via a
cephalic vein catheter, using a programmable
15 infusion pump at a delivery rate of 0.42
mg/minute. For each oligonucleotide, doses of 0,
0.5, 1, 2, 5 and 10 mg/kg are administered to two
animals each over a 10 minute infusion period.
Arterial blood samples are collected 10 minutes
20 prior to oligonucleotide administration and 2, 5,
10, 20, 40 and 60 minutes after the start of the
infusion, as well as 24 hours later. Serum is
used for determining complement CH50, using the
conventional complement-dependent lysis of sheep
25 erythrocyte procedure (see Kabat and Mayer, 1961,
supra). At the highest dose, phosphorothioate
oligonucleotide causes a decrease in serum
complement CH50 beginning within 5 minutes of the
start of infusion. Inverted hybrid and chimeric
30 oligonucleotides are expected to show a much
reduced or undetectable decrease in serum
complement CH50 under these conditions.

EXAMPLE 6

In Vivo Mitogenicity Studies

CD1 mice are injected intraperitoneally with
a dose of 50 mg/kg body weight of oligonucleotide
described in Example 2 above. Forty-eight hours
later, the animals are euthanized and the spleens
are removed and weighed. Animals treated with
inverted hybrid or inverted hybrid
oligonucleotides are expected to show no
significant increase in spleen weight, while those
treated with oligonucleotide phosphorothioates are
expected to show modest increases in spleen
weight.

EXAMPLE 7

In Vivo Clotting Studies

Rhesus monkeys are treated as in Example 5.
From the whole blood samples taken, plasma for
clotting assay is prepared, and the assay
performed, as described in Example 4. It is
expected that prolongation of aPTT will be
substantially reduced for both inverted hybrid
oligonucleotides and for inverted chimeric
oligonucleotide, relative to traditional
oligonucleotide phosphorothioates.

EXAMPLE 8

RNase H Activity Studies

To determine the ability of inverted hybrid
oligonucleotides and inverted chimeric
oligonucleotides to activate RNase H when bound to
a complementary RNA molecule, the following
experiments were performed. Each type of
oligonucleotide described in Example 2 above was
incubated together with a molar equivalent
quantity of complimentary oligoribonucleotide
(0.266 micromolar concentration of each), in a
cuvette containing a final volume of 1 ml RNase H
buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 0.1 M
KCl, 2% glycerol, 0.1 mM DTT). The samples were
heated to 95°C, then cooled gradually to room
temperature to allow annealing to form duplexes.
Annealed duplexes were incubated for 10 minutes at
37°C, then 5 units RNase H was added and data
collection commenced over a three hour period.
Data was collected using a spectrophotometer (GBC
920, GBC Scientific Equipment, Victoria,
Australia) at 259 nm. RNase H degradation was
determined by hyperchromic shift.

As expected, phosphodiester oligonucleotides
behaved as very good co-substrates for RNase H-
mediated degradation of RNA, with a degradative
half-life of 8.8 seconds. Phosphorothioate
oligonucleotides produced an increased half-life
of 22.4 seconds. Introduction of a 2'-O-methyl
ribonucleotide segment at either end of the
oligonucleotide further worsened RNase H activity
(half-life = 32.7 seconds). In contrast,

introducing a 2'-O-methyl segment into the middle of the oligonucleotide (inverted hybrid structure) always resulted in improved RNase H-mediated degradation. When a region of 13 2'-O-methylribonucleoside phosphodiester was flanked on both sides by phosphorothioate DNA, the best RNase H activity was observed, with a half-life of 7.9 seconds. Introduction of large blocks of methylphosphonate-linked nucleosides at the 3' end of the oligonucleotide either had no effect or caused further deterioration of RNase H activity even when in a chimeric configuration. Introduction of methylphosphonate linked nucleosides at the 5' end, however, improved RNase H activity, particularly in a chimeric configuration with a single methylphosphonate linker at the 3' end (best half-life = 8.1 seconds). All inverted chimeric oligonucleotides with methylphosphonate core regions flanked by phosphorothioate regions gave good RNase results, with a half-life range of 9.3 to 14.4 seconds. These results indicate that the introduction of inverted hybrid or inverted chimeric structure into phosphorothioate-containing oligonucleotides can restore some or all of the ability of the oligonucleotide to act as a co-substrate for RNase H, a potentially important attribute for an effective antisense agent.

EXAMPLE 9

Melting Temperature Studies

To determine the effect of inverted hybrid or inverted chimeric structure on stability of the duplex formed between an antisense oligonucleotide

and a target molecule, the following experiments were performed. Thermal melting (T_m) data were collected using a spectrophotometer (GBC 920, GBC Scientific Equipment, Victoria, Australia), which has six 10 mm cuvettes mounted in a dual carousel. In the T_m experiments, the temperature was directed and controlled through a peltier effect temperature controller by a computer, using software provided by GBC, according to the manufacturer's directions. T_m data were analyzed by both the first derivative method and the mid-point method, as performed by the software. T_m experiments were performed in a buffer containing 10 mM PIPES, pH 7.0, 1 mM EDTA, 1 M NaCl. A refrigerated bath (VWR 1166, VWR, Boston, MA) was connected to the peltier-effect temperature controller to absorb the heat. Oligonucleotide strand concentration was determined using absorbance values at 260 nm, taking into account extinction coefficients.

EXAMPLE 10

Tumor Growth and Antisense Treatment

LS-174T human colon carcinoma cells (1×10^6 cells) were inoculated subcutaneously (s.c.) into the left flank of athymic mice. A single dose of RI_α antisense hybrid (Oligo 164, SEQ ID NO:4), inverted hybrid (Oligo 166, SEQ ID NO:6), or inverted chimeric (Oligo 190, SEQ ID NO:1) oligonucleotides or control oligonucleotide (Oligo 169, SEQ ID NO:7); Oligo 168 (SEQ ID NO:5); Oligo 188, SEQ ID NO:3)) as shown in Table 1 (1 mg per 0.1 ml saline per mouse), or saline (0.1 ml per

mouse), was injected s.c. into the right flank of mice when tumor size reached 80 to 100 mg, about 1 week after cell inoculation. Tumor volumes were obtained from daily measurement of the longest and shortest diameters and calculation by the formula, $4/3\pi r^3$ where $r = (\text{length} + \text{width})/4$. At each indicated time, two animals from the control and antisense-treated groups were killed, and tumors were removed and weighed. The results are shown in FIG. 1. These results show that the size of the tumor in the animal treated with the inverted hybrid oligonucleotide 166 having SEQ ID NO:6 was surprisingly smaller from three days after injection onward than the phosphorothioate oligonucleotide 164 having SEQ ID NO:1. That this effect was sequence-specific is also demonstrated in FIG. 1: control oligonucleotide 168 (SEQ ID NO:3) has little ability to keep tumor size at a minimum relative to the hybrid and inverted hybrid oligonucleotides.

EXAMPLE 11

Photoaffinity Labelling and Immunoprecipitation of RI_o Subunits

The tumors are homogenized with a Teflon/glass homogenizer in ice-cold buffer (Tris-HCl, pH 7.4, 20 mM; NaCl, 100 mM; NP-40, 1%; sodium deoxycholate, 0.5%; MgCl₂, 5 mM; pepstatin, 0.1 mM; antipain, 0.1 mM; chymostatin, 0.1 mM; leupeptin, 0.2 mM; aprotinin, 0.4 mg/ml; and soybean trypsin inhibitor, 0.5 mg/ml; filtered through a 0.45- μ m pore size membrane), and

centrifuged for 5 min in an Eppendorf microfuge at 4°C. The supernatants are used as tumor extracts.

5 The amount of PKA RI α subunits in tumors is determined by photoaffinity labelling with 8-N $_3$ -[32 P]cAMP followed by immunoprecipitation with RI α antibodies as described by Tortora et al. (Proc. Natl. Acad. Sci. (USA) (1990) **87**:705-708). The photoactivated incorporation of 8-N $_3$ -[32 P]cAMP (60.0 Ci/m-mol), and the immunoprecipitation using the anti-RI α or anti-RII β antiserum and protein A Sepharose and SDS-PAGE of solubilized antigen-antibody complex follows the method previously described (Tortora et al. (1990) *Proc. Natl. Acad. Sci. (USA)* **87**:705-708; Ekanger et al. (1985) *J. Biol. Chem.* **260**:3393-3401). It is expected that the amount of RI α in tumors treated with hybrid, inverted hybrid, and inverted chimeric oligonucleotides of the invention will be reduced compared with the amount in tumors treated with mismatch, straight phosphorothioate, or straight phosphodiester oligonucleotide controls, saline, or other controls.

25

EXAMPLE 12

cAMP-Dependent Protein Kinase Assays

30 Extracts (10 mg protein) of tumors from antisense-, control antisense-, or saline-treated animals are loaded onto DEAE cellulose columns (1 x 10 cm) and fractionated with a linear salt gradient (Rohlf et al. (1993) *J. Biol. Chem.* **268**:5774-5782). PKA activity is determined in the

absence or presence of 5 μ M cAMP as described
below (Rohlf et al. (1993) *J. Biol. Chem.* **268**:5774-
5782). cAMP-binding activity is measured by the
method described previously and expressed as the
5 specific binding (Tagliaferri et al. (1988) *J. Biol.*
Chem. **263**:409-416).

After two washes with Dulbecco's phosphate-
buffered saline, cell pellets (2×10^6 cells) are
10 lysed in 0.5 ml of 20 mM Tris (pH 7.5), 0.1 mM
sodium EDTA, 1 mM dithiothreitol, 0.1 mM
pepstatin, 0.1 mM antipain, 0.1 mM chymostatin,
0.2 mM leupeptin, 0.4 mg/ml aprotinin, and 0.5
mg/ml soybean trypsin inhibitor, using 100 strokes
15 of a Dounce homogenizer. After centrifugation
(Eppendorf 5412) for 5 min, the supernatants are
adjusted to 0.7 mg protein/ml and assayed (Uhler
et al. (1987) *J. Biol. Chem.* **262**:15202-15207)
immediately. Assays (40 μ l total volume) are
20 performed for 10 min at 300°C and contained 200 μ M
ATP, 2.7×10^6 cpm γ [32 P]ATP, 20 mM MgCl_2 , 100 μ M
Kemptide (Sigma K-1127) (Kemp et al. (1977) *J. Biol.*
Chem. **252**:4888-4894), 40 mM Tris (pH 7.5), \pm 100
 μ M protein kinase inhibitor (Sigma P-3294) (Cheng
25 et al. (1985) *Biochem. J.* **231**:655-661), \pm 8 μ M cAMP
and 7 μ g of cell extract. The phosphorylation of
Kemptide is determined by spotting 20 μ l of
incubation mixture on phosphocellulose filters
(Whatman, P81) and washing in phosphoric acid as
30 described (Roskoski (1983) *Methods Enzymol.* **99**:3-6).
Radioactivity is measured by liquid scintillation
using Econofluor-2 (NEN Research Products NEF-
969). It is expected that PKA and cAMP binding

activity will be reduced in extracts of tumors treated with the hybrid, inverted hybrid, and inverted chimeric oligonucleotides of the invention.

5

EXAMPLE 13

EFFECT OF HYB 165 WITH DOCETAXEL AND MONOCLONAL ANTIBODY MAb C225 ON THE GROWTH OF ZR75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials.

HYB 165, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 165, *GCGUGCCTCCTCACUGGC* and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. Docetaxel was a kind gift from Rhone Poulenc Rorer, Origgio, Italy, and used after dilution in appropriate solvent as 100x concentrated stock. The monoclonal antibody MAb C225 is a human-mouse chimeric IgG₁ that binds to the EGFR, competes with natural ligands for receptor binding and blocks the EGFR tyrosine kinase activation. Clinical grade MAb C225 was kindly provided by Dr. H. Waksal, ImClone Systems, New York, NY.

Cell lines.

ZR75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth.

Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various

concentrations of docetaxel (day 0). HYB 165 and C225 were added together after 12 hrs (day 1) and on day 3. Twelve days after the last treatment, cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

Results

HYB 165 0.1 μ M, which alone causes about 8% inhibition and C225 0.25 μ g/ml, which alone causes about 8% inhibition, were added to ZR75-1 cells treated with docetaxel 0.01 nM, which alone causes less than 12% inhibition, determining an average 93% inhibition. See Figure 2.

Conclusions

HYB 165, MAb C225 and docetaxel, at the low inhibitory doses of 0.1 μ M, 0.25 μ g/ml and 0.01 nM, respectively, cooperatively inhibit the growth of ZR75-1 cells when used in combination.

Figure Legend

Effect of the combination of Hyb 165, the MAb C225 and Docetaxel on the soft agar growth of ZR-75-1 breast cancer cells. The doses of the different agents are: HYB 165, 0.1 and 0.5 μ M; Docetaxel, 0.01 nM; MAb C225, 0.25 μ g/ml.

Data are expressed as percentage growth inhibition in reference to the growth of untreated control cells. The height of the bars on the left represents the sum of the individual agents effects and the expected percentage growth inhibition if drugs are additive when used in combination. The total height of the solid bar indicates the actual observed growth inhibition when drugs were used in combination. Therefore, the differences between the heights of the paired bars reflect the magnitude of synergism of growth inhibition.

The data represent means and standard errors of triplicate determinations of two experiments.

EXAMPLE 14

EFFECT OF HYB 508 WITH DOCETAXEL AND MONOCLONAL ANTIBODY MAb C225 ON THE GROWTH OF ZR75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials.

HYB 508, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 508, ***GCAUGCTTCCACACAGGC*** and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligonucleotide of HYB 165, containing four mismatched nucleotides (underlined). Docetaxel was a kind gift from Rhone Poulenc Rorer, Origgio, Italy, and used after dilution in appropriate solvent as 100x concentrated stock. The monoclonal antibody MAb C225 is a human-mouse chimeric IgG₁ that binds to the EGFR, competes with natural ligands for receptor binding and blocks the EGFR tyrosine kinase activation. Clinical grade MAb C225 was kindly provided by Dr. H. Waksal, ImClone Systems, New York, NY.

Cell lines.

ZR75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth.

Cells (10^4 cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of docetaxel (day 0). The HYB 508 and C225 were added together after 12 hrs (day 1) and on day 3. Twelve days after the last treatment, cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

Results

HYB 508 0.5 μ M, which alone causes about 6% inhibition and C225 0.25 μ g/ml, which alone causes about 8% inhibition, were added to ZR75-1 cells treated with docetaxel 0.01 nM, which alone causes about 12% inhibition, determining an average 26% inhibition. See Figure 3.

Conclusions

HYB 508, MAb C225 and docetaxel, at the low inhibitory doses of 0.5 μ M, 0.25 μ g/ml and 0.01 nM, respectively, showed no cooperative antiproliferative effect on the growth of ZR-75-1 cells when used in combination.

Figure Legend

Effect of the combination of Hyb 508, the MAb C225 and Docetaxel on the soft agar growth of ZR-75-1 breast cancer cells. The doses of the different agents are: HYB 508, 0.5 μ M; Docetaxel, 0.01 nM; MAb C225, 0.25 μ g/ml.

Data are expressed as percentage growth inhibition in reference to the growth of untreated control cells. The height of the bars on the left represents the sum of the individual agents effects and the expected percentage growth inhibition if drugs are additive when used in combination. The total height of the solid bar indicates the actual observed growth inhibition when drugs were used in combination. Therefore, the differences between the heights of the paired bars reflect the magnitude of synergism of growth inhibition.

The data represent means and standard errors of triplicate determinations of two experiments.

EXAMPLE 15

EFFECT OF HYB 165 WITH OR WITHOUT PACLITAXEL ON THE GROWTH OF GEO HUMAN COLON CANCER CELLS

MATERIALS AND METHODS

Materials.

HYB 165, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 165, ***GCGUGCCTCCTCACUGGC*** and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. Paclitaxel was purchased from Sigma (St Louis, MO) and used after dilution in appropriate solvent as 100x concentrated stock.

Cell lines.

GEO human colon cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in McCoy medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth.

Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of paclitaxel (day 0). The HYB 165 was added after 12 hrs (day 1) and on day 2, 3 and 4. 12 days after the last treatment, cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

Results

A dose-dependent effect of paclitaxel at doses ranging between 0.1 and 10 nM was observed, determining up to about 60% growth inhibition. HYB 165 0.5 μ M, which alone causes about 20% inhibition, was added to GEO cells treated with *a*) paclitaxel 1 nM, which alone causes less than 5% inhibition, determining an average 40% inhibition; *b*) paclitaxel 5 nM, which alone causes about 20% inhibition, determining an average 62% inhibition; *c*) paclitaxel 10 nM, which alone causes about 58% inhibition, determining an average 86% inhibition. See Figure 4.

Conclusions

HYB 165 at the low inhibitory dose of 0.5 μ M cooperatively inhibit the growth of GEO cells when used in a sequential combination with different doses of paclitaxel.

EXAMPLE 16

EFFECT OF HYB 165 AND ITS CONTROL HYB 508 ON THE GROWTH OF 1A9PTX22 HUMAN OVARIAN CANCER CELLS

MATERIALS AND METHODS

Materials. 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human R1 α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCCTCACUGGC*; HYB 508, *GCAUGCTTCCACACAGGC*. HYB 165 and HYB 508 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines. The 1A9PTX22 cell line, a paclitaxel (PTX)-resistant clone of the human ovarian carcinoma cell line 1A9, was isolated by exposing 1A9 cells to 5 ng/ml PTX in the presence of 5 μ g/ml verapamil, a P glycoprotein antagonist. 1A9PTX22 cells were kindly provided by Dr. Giannakakou, NCI Bethesda, MD, USA. Cells were maintained in RPMI medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4 penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) 15 ng/ml PTX and 5 μ g/ml verapamil in a humidified atmosphere of 95% air and 5% CO₂ at 37° C. 7 days before experiments were performed, PTX and verapamil were removed from culture medium.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB508 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

Two different 18-mer MBO complementary to the R1 α subunit of PKAI sequence, HYB 165 and its control oligomer HYB 508, differing only in 4 nucleotide bases, were tested to study their effect on soft agar growth of 1A9 human ovarian cancer cells. While HYB 165 determined a dose-dependent inhibition of colony formation at doses ranging between 0.1 and 2.5 μ M in all cell lines, the HYB 508 control sequence showed a modest or no growth inhibitory effect. HYB 165 determined an inhibition of 1A9PTX22 cell growth of approximately 5% at a dose of 0.1 μ M, of about 50% at 0.5 μ M, of about 82% at 1 μ M and achieved over 95% at 2.5 μ M (Fig. 2). Conversely, HYB 508 caused a growth inhibition which at the highest dose of 2.5 μ M achieved 10%. See Figure 5.

CONCLUSIONS

HYB 165 causes a dose-dependent growth inhibitory effect on 1A9PTX22 cells, while its mismatched control oligomer causes a modest growth inhibitory effect (no more than 10%).

EXAMPLE 17

EFFECT OF HYB 165 AND ITS CONTROL HYB 508 ON THE GROWTH OF 1A9PTX10 HUMAN OVARIAN CANCER CELLS

MATERIALS AND METHODS

Materials. 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCCTCACUGGC*; HYB 508, *GCAUGCTTCCACACAGGC*. HYB 165 and HYB 508 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines. The 1A9PTX10 cell line, a paclitaxel (PTX)-resistant clone of the human ovarian carcinoma cell line 1A9, was isolated by exposing 1A9 cells to 5 ng/ml PTX in the presence of 5 μ g/ml verapamil, a P glycoprotein antagonist. 1A9PTX10 cells were kindly provided by Dr. Giannakakou, NCI Bethesda, MD, USA. Cells were maintained in RPMI medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 U/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) 15 ng/ml PTX and 5 μ g/ml verapamil in a humidified atmosphere of 95% air and 5% CO₂ at 37° C. 7 days before experiments were performed, PTX and verapamil were removed from culture medium.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB508 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

Two different 18-mer MBO complementary to the RI α subunit of PKAI sequence, HYB 165 and its control oligomer HYB 508, differing only in 4 nucleotide bases, were tested to study their effect on soft agar growth of 1A9 human ovarian cancer cells. While HYB 165 determined a dose-dependent inhibition of colony formation at doses ranging between 0.1 and 2.5 μ M in all cell lines, the HYB 508 control sequence showed a modest or no growth inhibitory effect. HYB 165 determined an inhibition of 1A9PTX10 cell growth of approximately 5% at a dose of 0.1 μ M, of about 43% at 0.5 μ M, of about 70% at 1 μ M and achieved over 85% at 2.5 μ M (Fig. 2). Conversely, HYB 508 caused a growth inhibition which at the highest dose of 2.5 μ M achieved 10%. See Figure 6.

CONCLUSIONS

HYB 165 causes a dose-dependent growth inhibitory effect on 1A9PTX10 cells, while its mismatched control oligomer causes a modest growth inhibitory effect (no more than 10%).

EXAMPLE 18

EFFECT OF HYB 165 AND ITS CONTROL HYB 508 ON THE GROWTH OF 1A9 HUMAN OVARIAN CANCER CELLS

MATERIALS AND METHODS

Materials. 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCCTCACUGGC*; HYB508, *GCAUGCTTCCACACAGGC*. HYB 165 and HYB 508 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines. The 1A9 cell line is a clone of the human ovarian carcinoma cell line, A2780. 1A9 cells were kindly provided by Giannakakou, NCI Bethesda, MD, USA. Cells were maintained in RPMI medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4 penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB508 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

Two different 18-mer MBOs complementary to the RI α subunit of PKAI sequence, HYB 165 and its control oligomer HYB 508, differing only in 4 nucleotide bases, were studied to evaluate their effect on soft agar growth of 1A9 human ovarian cancer cells. While HYB 165 determined a dose-dependent inhibition of colony formation at doses ranging between 0.1 and 2.5 μ M in all cell lines, the HYB 508 control sequence showed a modest or no growth inhibitory effect. HYB 165 determined an inhibition of 1A9 cell growth of approximately 5% at a dose of 0.1 μ M, of about 41% at 0.5 μ M, of about 90% at 1 μ M and achieved over 95% at 2.5 μ M (Fig. 2). Conversely, HYB 508 caused a growth inhibition which at the highest dose of 2.5 μ M achieved 20% inhibition. See Figure 7.

CONCLUSIONS

HYB 165 causes a dose-dependent growth inhibitory effect on 1A9 cells, while its mismatched control oligomer causes a modest growth inhibitory effect (no more than 20%).

EXAMPLE 19

EFFECT OF HYB 508 WITH OR WITHOUT MONOCLONAL ANTIBODY Mab C225 ON THE GROWTH OF ZR-75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials. HYB 508, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 508, *GCAUGCTTCCACACAGGC* and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligonucleotide of HYB 165, containing four mismatched nucleotides (underlined). The monoclonal antibody Mab C225 is a human-mouse chimeric IgG₁ that binds to the EGFR, competes with natural ligands for receptor binding and blocks the EGFR tyrosine kinase activation. Clinical grade MAbC225 was kindly provided by Dr. H. Waksal, ImClone Systems, New York, NY.

Cell lines. ZR-75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of Mab C225 and/or of HYB508 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

HYB 508 0.5 μ M (i-l), which alone causes about 5% inhibition of ZR-75-1 cell growth, was used in combination with i) Mab C225 0.25 μ g/ml, which alone causes about 10% inhibition, determining an average 12% inhibition; j) Mab C225 0.5 μ g/ml, which alone causes about 47% inhibition, determining an average 45% inhibition; k) Mab C225 1 μ g/ml, which alone causes about 68% inhibition, determining an average 77% inhibition; l) Mab C225 2.5 μ g/ml, which alone causes about 76% inhibition, determining an average 82% inhibition. See Figure 8.

CONCLUSIONS

HYB 508 at the dose of 0.5 μ M showed no cooperative antiproliferative effect on the growth of ZR-75-1 cells when used in combination with different doses of Mab C225.

Figure Legend

Effect of the combination of two different agents on the growth of ZR-75-1 breast cancer cells. HYB 508 0.5 μ M (i-l) in combination with MAb C225 0.25 μ g/ml (i), 0.5 μ g/ml (j), 1 μ g/ml (k) and 2.5 μ g/ml (l).

Data are expressed as percentage growth inhibition in reference to the growth of untreated control cells. The height of the bars on the left represents the sum of the individual agents effects and the expected percentage growth inhibition if drugs are additive when used in combination. The total height of the solid bar indicates the actual observed growth inhibition when drugs were used in combination. Therefore, the differences between the heights of the paired bars reflect the magnitude of synergism of growth inhibition.

The data represent means and standard errors of triplicate determination of at least two experiments.

EXAMPLE 20

EFFECT OF HYB 165 AND HYB 618 ON THE GROWTH OF OVCAR-3 OVARIAN CANCER CELLS

MATERIALS AND METHODS

Materials. 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCTCACUGGC*; HYB618, *GCAUGCATCCGCACAGGC*. HYB 165 and HYB 618 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 618 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines. OVCAR human ovarian cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM and HAM'S F-12 (1:1) supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4; penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB295 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

Results

Two different 18-mer MBO complementary to the RI α subunit of PKAI sequence, HYB 165 and its control oligomer HYB 618, differing only in 4 nucleotide bases, were tested to study their effect on soft agar growth of GEO human colon cancer cells. While HYB 165 determined a dose-dependent inhibition of colony formation at doses ranging between 0.1 and 2.5 μ M in all cell lines, the HYB 618 control sequence showed a modest or no growth inhibitory effect. HYB 165 determined an inhibition of OVCAR-3 cell growth of approximately 25% at a dose of 0.1 μ M, of about 58% at 0.5 μ M, of about 75% at 1 μ M and about 95% at 2.5 μ M (Fig. 2). Conversely, HYB 618 caused a growth inhibition which at the highest dose of 2.5 μ M achieved 15%. See Figure 9.

Conclusions

HYB 165 causes a dose-dependent growth inhibitory effect on OVCAR-3 cells, while its mismatched control oligomer causes a modest growth inhibitory effect (less than 15%).

EXAMPLE 21

EFFECT OF HYB 165 WITH OR WITHOUT DOCETAXEL ON THE GROWTH OF ZR75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials. HYB 165, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 165, *GCGUGCCTCCTCACUGGC* and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. Docetaxel was a kind gift from Rhone Poulenc Rorer, Origgio, Italy, and used after dilution in appropriate solvent as 100x concentrated stock.

Cell lines. ZR75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of docetaxel (day 0). The HYB 165 was added after 12 hrs (day 1) and on day 3. Twelve days after the last treatment, cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

Results

A dose-dependent effect of docetaxel at doses ranging between 0.01 and 0.3 nM was observed, determining up to about 80% growth inhibition. HYB 165 0.1 (a-d) μ M, which alone causes about 5% inhibition, was added to ZR75-1 cells treated with a) docetaxel 0.01 nM, which alone causes less than 15% inhibition, determining an average 40% inhibition; b) docetaxel 0.03 nM, which alone causes about 40% inhibition, determining an average 70% inhibition; c) docetaxel 0.1 nM, which alone causes about 72% inhibition, determining an average 86% inhibition; d) docetaxel 0.3 nM, which alone causes about 85% inhibition, determining an average 97%.

HYB 165 0.5 μ M (e-f), which alone causes about 15% inhibition, was added to ZR75-1 cells treated with e) docetaxel 0.01 nM, which alone causes less than 15% inhibition, determining an average 65% inhibition; f) docetaxel 0.03 nM, which alone causes about 40% inhibition, determining an average 66% inhibition; g) docetaxel 0.1 nM, which alone causes about 72% inhibition, determining an average 86% inhibition; h) docetaxel 0.3 nM, which alone causes about 85% inhibition, determining an average 99% inhibition. See Figure 10.

Conclusions

HYB 165 at the low inhibitory doses of 0.1 μ M and 0.5 μ M cooperatively inhibits the growth of ZR75-1 cells when used in a sequential combination with different doses of docetaxel.

Figure Legend

Effect of the combination of two different agents on the growth of ZR-75-1 breast cancer cells. HYB 165 0.1 μ M (a-d) and 0.5 μ M (e-f) in combination with Docetaxel 0.01 nM (a-e); 0.03 nM (b-f); 0.1 nM (c-g); 0.3 nM (d-h).

Data are expressed as percentage growth inhibition in reference to the growth of untreated control cells. The height of the bars on the left represents the sum of the individual agents effects and the expected percentage growth inhibition if drugs are additive when used in combination. The total height of the solid bar indicates the actual observed growth inhibition when drugs were used in combination. Therefore, the differences between the heights of the paired bars reflect the magnitude of synergism of growth inhibition.

The data represent means and standard errors of triplicate determination of at least two experiments.

EXAMPLE 22

EFFECT OF HYB 508 WITH OR WITHOUT DOCETAXEL ON THE GROWTH OF ZR-75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials. HYB 508, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 508, *GCAUGCITCCACACAGGC* and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligonucleotide of HYB 165, containing four mismatched nucleotides (underlined). Docetaxel was a kind gift from Rhone Poulenc Rorer, Origgio, Italy, and used after dilution in appropriate solvent as 100x concentrated stock.

Cell lines. ZR-75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 U/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of docetaxel (day 0). The HYB 508 was added after 12 hrs and on day 2, 3 and 4. After 12 days the cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

A dose-dependent effect of docetaxel at doses ranging between 0.01 and 0.3 nM was observed, determining up to about 80% growth inhibition. HYB508 0.5 μ M (i-l), which alone causes about 7% inhibition, was added to ZR75-1 cells treated with cells treated with : *i*) docetaxel 0.01 nM, which alone causes less than 15% inhibition, determining an average 20% inhibition; *j*) docetaxel 0.03 nM, which alone causes about 40% inhibition, determining an average 42% inhibition; *k*) docetaxel 0.1 nM, which alone causes about 72% inhibition, determining an average 78% inhibition; *l*) docetaxel 0.3 nM, which alone causes about 85% inhibition, determining an average 82%. See Figure 11.

Conclusions

HYB 508 at the dose of 0.5 μ M showed no cooperative antiproliferative effect on the growth of ZR-75-1 cells when used in a sequential combination with different doses of docetaxel.

Figure Legend

Effect of the combination of two different agents on the growth of ZR-75-1 breast cancer cells. HYB 508 0.5 μ M (i-l) in combination with Docetaxel 0.01 nM (i); 0.03 nM (j); 0.1 nM (k); 0.3 nM (l).

Data are expressed as percentage growth inhibition in reference to the growth of untreated control cells. The height of the bars on the left represents the sum of the individual agents effects and the expected percentage growth inhibition if drugs are additive when used in combination. The total height of the solid bar indicates the actual observed growth inhibition when drugs were used in combination. Therefore, the differences between the heights of the paired bars reflect the magnitude of synergism of growth inhibition.

The data represent means and standard errors of triplicate determination of at least two experiments.

EXAMPLE 23

EFFECT OF HYB 165 WITH OR WITHOUT MONOCLONAL ANTIBODY MAb C225 ON THE GROWTH OF ZR-75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials. HYB 165, a 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described was provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequence: HYB 165, *GCGUGCCTCCTCACUGGC*, and contains 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. The monoclonal antibody MAb C225 is a human-mouse chimeric IgG₁ that binds to the EGFR, competes with natural ligands for receptor binding and blocks the EGFR tyrosine kinase activation. Clinical grade Mab C225 was kindly provided by Dr. H. Waksal, ImClone Systems, New York, NY.

Cell lines. ZR-75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of Mab C225 and/or of HYB165 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

HYB 165 0.1 μ M (a-d), which alone causes about 2% inhibition of ZR-75-1 cell growth, was used in combination with a) Mab C225 0.25 μ g/ml, which alone causes about 10% inhibition, determining an average 37% inhibition; b) Mab C225 0.5 μ g/ml, which alone causes about 47% inhibition, determining an average 65% inhibition; c) Mab C225 1 μ g/ml, which alone causes about 68% inhibition, determining an average 85% inhibition; d) Mab C225 2.5 μ g/ml, which alone causes about 76% inhibition, determining an average 90% inhibition.

HYB 165 at the higher dose of 0.5 μ M (e-h), which alone causes about 10% inhibition of ZR-75-1 cell growth, was used in combination with e) Mab C225 0.25 μ g/ml, which alone causes about 10% inhibition, determining an average 57% inhibition; f) Mab C225 0.5 μ g/ml, which alone causes about 47% inhibition, determining an average 70% inhibition; g) Mab C225 1 μ g/ml, which alone causes about 68% inhibition, determining an average 90% inhibition; h) Mab C225 2.5 μ g/ml, which alone causes about 76% inhibition, determining an average 98% inhibition. See Figure 12.

CONCLUSIONS

HYB 165 at the low inhibitory dose of 0.1 μ M and 0.5 μ M cooperatively inhibit the growth of ZR-75-1 cells when used in combination with different doses of Mab C225.

Figure Legend

Effect of the combination of two different agents on the growth of ZR-75-1 breast cancer cells. HYB 165 0.1 μ M (a-d) and 0.5 μ M (e-f) or HYB-508 0.5 μ M (i-l) in combination with MAb C225 0.25 μ g/ml (a,e,i), 0.5 μ g/ml (b,f,j), 1 μ g/ml (c,g,k) and 2.5 μ g/ml (d,h,l).

Data are expressed as percentage growth inhibition in reference to the growth of untreated control cells. The height of the bars on the left represents the sum of the individual agents effects and the expected percentage growth inhibition if drugs are additive when used in combination. The total height of the solid bar indicates the actual observed growth inhibition when drugs were used in combination. Therefore, the differences between the heights of the paired bars reflect the magnitude of synergism of growth inhibition.

The data represent means and standard errors of triplicate determination of two experiments.

EXAMPLE 24

EFFECT OF HYB 165 AND HYB 295 ON THE GROWTH OF ZR-75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials. 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCCTCACUGGC*; HYB295, *GCAUGCATCCGCACAGGC*. HYB 165 and HYB 295 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 295 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines. ZR-75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB295 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

RESULTS

Two different 18-mer MBO complementary to the RI α subunit of PKAI sequence, HYB 165 and its control oligomer HYB 295, differing only in 4 nucleotide bases, were tested to study their effect on soft agar growth of ZR-75-1 human breast cancer cells. While HYB 165 determined a dose-dependent inhibition of colony formation at doses ranging between 0.1 and 2.5 μ M in all cell lines, the HYB 295 control sequence showed a modest or no growth inhibitory effect. HYB 165 determined an inhibition of ZR-75-1 cell growth of approximately 5% at a dose of 0.1 μ M, of about 34% at 1 μ M and achieved over 85% at 2.5 μ M (Fig. 2). Conversely, HYB 295 caused a growth inhibition which at the highest dose of 2.5 μ M achieved 10%. See Figure 13.

CONCLUSIONS

HYB 165 causes a dose-dependent growth inhibitory effect on ZR-75-1 cells, while its mismatched control oligomer causes a modest growth inhibitory effect (no more than 10%).

EXAMPLE 25

EFFECT OF HYB 165 AND HYB 508 ON THE GROWTH OF ZR-75-1 HUMAN BREAST CANCER CELLS

MATERIALS AND METHODS

Materials.

18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCCTCACUGGC*; HYB 508, *GCAUGCTTCCACACAGGC*. HYB 165 and HYB 508 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 508 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines.

ZR-75-1 human breast cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB508 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted.

Experiments were performed twice in triplicate.

Results

Two different 18-mer MBO complementary to the RI α subunit of PKAI sequence, HYB 165 and its control oligomer HYB 508, differing only in 4 nucleotide bases, were tested to study their effect on soft agar growth of ZR-75-1 human breast cancer cells. While HYB 165 determined a dose-dependent inhibition of colony formation at doses ranging between 0.1 and 2.5 μ M in all cell lines, the HYB 508 control sequence showed a modest or no growth inhibitory effect. HYB 165 determined an inhibition of ZR-75-1 cell growth of approximately 5% at a dose of 0.1 μ M, of about 34% at 1 μ M and achieved over 85% at 2.5 μ M (Fig. 2). Conversely, HYB 508 caused a growth inhibition which at the highest dose of 2.5 μ M achieved 10%. See Figure 14.

Conclusions

HYB 165 causes a dose-dependent growth inhibitory effect on ZR-75-1 cells, while its mismatched control oligomer causes a modest growth inhibitory effect (no more than 10%).

EXAMPLE 26

EFFECT OF HYB 165 AND HYB 295 ON THE GROWTH OF GEO COLON CANCER CELLS

MATERIALS AND METHODS

Materials. 18-mer mixed backbone oligonucleotides (MBO) targeted against the N-terminal 8-13 codons of the human RI α regulatory subunit of PKA, synthesized by the procedure previously described were provided by Hybridon Inc., Cambridge, MA. The antisense used had the following sequences: HYB 165, *GCGUGCCTCCTCACUGGC*; HYB295, *GCAUGCATCCGCACAGGC*. HYB 165 and HYB 295 are chimeric compounds containing 2-O-methyl-modified ribonucleotide bases (bold italics) at the 5' and 3' ends and unmodified oligodeoxynucleotide bases in the middle. HYB 295 is a control oligo containing four mismatched nucleotides as underlined.

Cell lines. GEO human colon cancer cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in McCoy's Medium 5A supplemented with 10% heat-inactivated FBS, 20 mM HEPES, pH 7.4, penicillin (100 UI/ml), streptomycin (100 μ g/ml) and 4 mM glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95% air and 5% CO₂ at 37° C.

Soft agar growth. Cells (10⁴ cells/well) were seeded in 0.5 ml of 0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson) and treated with various concentrations of HYB 165 or HYB295 every 48 hours for three times. After 12 days the cells were stained with nitroblue tetrazolium (Sigma, St. Louis, MO) and colonies larger than 0.05 mm were counted. See Figure 15.

Experiments were performed twice in triplicate.

EXAMPLE 27

HYB 165 inhibits tumor growth after i.p. or oral administration

5

We investigated the antitumor activity of HYB 165 (AS RI α) in nude mice bearing GEO colon cancer xenografts, using either the intraperitoneal (i.p.) or the oral route of administration. When established GEO tumors of approximately 0.2 cm³ were detectable, groups of 10 mice were treated i.p. with either HYB 165 or a control modified backbone oligonucleotide with a scrambled sequence, at 5 or 10 mg/kg/dose, daily on days 7 to 11 and 14 to 18. Figure 16A shows that i.p. administration of HYB 165 caused a dose-dependent inhibition of growth up to 40% at a dose of 10 mg/kg/dose. The control oligonucleotide produced no inhibition at 10 mg/kg/dose.

Following oral administration, modified backbone oligonucleotides (MBOs) are absorbed in the upper and lower part of the GI tract and distributed to major organs (S. Agrawal and R. Zhang, In: Antisense Research and Application, S. T. Crooke, ed.), Handbook of Experimental Pharmacology, Springer, Berlin, p. 525-543 (1998). Therefore, HYB 165 and the control oligonucleotide were administered to GEO tumor-bearing mice as described above, except that HYB 165 and the control oligonucleotide were administered orally. As shown in Figure 16B, at a dose of 10 mg/kg/dose, the two cycles of treatment with HYB 165 caused an average inhibition of tumor growth of about 60% as compared to untreated mice, while the tumor size of the mice treated with the

control scramble oligonucleotide was only slightly affected.

EXAMPLE 28

5

Oral HYB 165 cooperatively inhibits tumor growth and increases survival in combination with taxol.

10 On day 7 after tumor cell injection, one group of 10 mice was treated with taxol (20 mg/kg/dose, i.p.), and the treatment was repeated every 2 weeks (on day 21 and day 35) for a total of three cycles. Two other groups of mice were treated with either HYB 165 (AS RI α) or a control MBO with a scrambled sequence (10 mg/kg/dose, p.o.), daily for five days (days 8-12). Treatment was repeated every 2 weeks (days 22-26 and days 36-40) for a total of three cycles. Two more groups of mice were treated with taxol and either HYB 165 or the control MBO, administering the taxol (20 mg/kg/dose, i.p.) on day 7, followed by oral administration of either HYB 165 or the control MBO daily for five days (days 8-12). The sequential treatment was repeated with the same schedule every 2 weeks for a total of three cycles.

30 As illustrated in Figure 17A, treatment with either taxol or the HYB 165 alone inhibited tumor growth as compared to control untreated mice or to mice treated with the scramble MBO. HYB 165 was more effective than taxol, causing over 50% inhibition of tumor size at the completion of the three cycles of treatment. However, shortly after the end of treatment, GEO tumors resumed the growth rate of those in untreated mice or in mice

665001-2401400

treated with the scramble MBO. When taxol and HYB 165 were used in combination, a marked and sustained inhibition of tumor growth was observed. In fact, tumors of mice treated with taxol and HYB 165 grew very slowly for approximately 60 days following the end of treatment, at which time they resumed a faster growth rate (Figure 17A). Administration of the scramble MBO in combination with taxol produced an effect simiolar to that of taxol alone. Within approximately 5 weeks, GEO tumors reached a size not compatible with normal life in all untreated mice and in mice treated with the scramble MBO (Figure 17B). A slight increase in survival time was observed in the group treated with taxol alone, an effect similar to that observed in mice treated with taxol followed by the scramble MBO (data not shown). Treatment with HYB 165 alone also increased survival time as compared to the control group. The delayed GEO tumor growth observed in the group treated with taxol in combination with HYB 165 was accompanied by a prolonged mice life span, when, when analyzed with the log-rank test (N. Mantel, *Cancer Chem. Rep.*, 163-170 (1966)), was significantly different as compared to controls ($P < 0.0001$), to the taxol-treated group ($P < 0.0001$) or to the group treated with scramble MBO plus taxol ($P < 0.0001$). In fact, the only mice still alive at 10 weeks after tumor cell injection were those treated with the combination of taxol and HYB 165. Furthermore, about 50% of the mice in this group were still alive after 15 weeks. The combined treatment with taxol and HYB 165 was well

tolerated, since no weight loss or other signs of acute or delayed toxicity were observed.

EXAMPLE 29

5

Cooperative antitumor effect of HYB 165 with taxol is accompanied by inhibition of new vessels formation and growth factors production.

10

Tumor specimens from the different groups of mice were examined by histochemical analysis at different time points to evaluate the expression of a variety of biological parameters. Results of the analysis performed on tumor specimens after two cycles of treatment are presented in Table I. Treatment with HYB 165 inhibited expression of the target RI α protein in the tumor. This effect was further increased with HYB 165 was used in combination with taxol. No other treatment was able to affect RI α expression. These results suggest that inhibition of RI α expression is not dependent on growth inhibition.

15

20

25

30

TGF α and AR are growth factors which bind to EGFR and control human colon cancer growth through autocrine and paracrine mechanisms (F. Ciardiello and G. Tortora, *Clin. Cancer Res.* 4:821-828 (1998); D. S. Salomon, *Crit. Rev. Oncol. Hematol.* 19:183-232 (1995)). Unlike taxol, treatment with HYB 165 inhibited the expression of TGF α and AR. Inhibition of AR was further enhanced when taxol was used in combination with HYB 165. Moreover, the combination of taxol and HYB 165 almost completely suppressed cell proliferation, as demonstrated by Ki67 staining.

Loda et al. (*Nature Medicine* 3:231-234 (1997)) discloses that the cyclin-dependent kinase (CDK) inhibitor p27 is directly related to cell entry into S phase and proliferation and that reduction of its expression correlates with poor prognosis in colon cancer patients. Unlike taxol, HYB 165 alone is able to increase p27 expression. Moreover, a 2.5-fold increase in intensely positive cell staining for p27 was observed in the tumor samples from mice treated with taxol and antisense R1 α .

In recent years, the critical role of tumor-induced neovascularization in neoplastic development, progression and metastasis has been elucidated (J. I. Fokman, In: J. Mendelsohn et al., eds., *The Molecular Basis of Cancer*, pp 206-232, Philadelphia: WB Saunders (1995)). A reliable histologic estimate of novel blood vessels on tumor specimens is the microvessel count (MVC) in the most intense areas of neovascularization. In the present study, tumor-induced neovascularization was quantified by immunohistochemistry using an anti-Factor VIII related antigen monoclonal antibody (N. Weidner, *Breast Cancer Res. Treat.*, 36:169-180 (1995)). As shown in Table I, a significant inhibition of staining was obtained with HYB 165 (about 80%) as well as with taxol (over 60%), as compared to samples from untreated mice or mice treated with the scramble MBO. Combined treatment with taxol and HYB 165 completely suppressed vessel formation in GEO tumors, demonstrating that the cooperative antitumor effect was associated with the marked inhibition of several factors controlling cell

cycle, proliferation and angiogenesis of this human colon cancer model.

5

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

10
15

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Agrawal, Sudhir
- (ii) TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE
- (iii) NUMBER OF SEQUENCES: 8
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Lappin & Kusmer
 - (B) STREET: 200 State Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02109
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kerner, Ann-Louise
 - (B) REGISTRATION NUMBER: 33,523
 - (C) REFERENCE/DOCKET NUMBER: HYZ-050
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-330-1300
 - (B) TELEFAX: 617-330-1311

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCGTGCCTCC TCACTGGC

18

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCGCGCCTCC TCGCTGGC

18

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCATGCTTCC ACACAGGC

18

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCGUGCCTCC TCACUGGC

18

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCGCGCCTCC TCGCUGGC

18

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCGTGCCUCC UCACTGGC

18

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCGCGCCUCC UCGCTGGC

18

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCATGCAUCC GCACAGGC

18

What is claimed is:

1. A method for inhibiting proliferation of cancer cells comprising

5 (a) administering to the cells a first agent comprising a synthetic, modified oligonucleotide complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI α , the modified oligonucleotide
10 having from about 15 to about 30 nucleotides and being a hybrid, inverted hybrid, or inverted chimeric oligonucleotide,

the hybrid oligonucleotide comprising a region of at least two deoxyribonucleotides,
15 flanked by 3' and 5' flanking ribonucleotide regions each having at least four ribonucleotides,

the inverted hybrid oligonucleotide comprising a region of at least four ribonucleotides flanked by 3' and 5' flanking
20 deoxyribonucleotide regions of at least two deoxyribonucleotides,

and the inverted chimeric oligonucleotide comprising an oligonucleotide nonionic region of at least four nucleotides flanked by two
25 oligonucleotide phosphorothioate regions; and

(b) administering to the cells a second agent comprising an antibody that binds to epidermal growth factor receptor (EGFR) or a cytotoxic agent selected from the group consisting
30 of taxanes, platinum-derived agents, and topoisomeraseII-selective drugs;

wherein the administering steps may be performed simultaneously or sequentially in any order.

2. The method of claim 1, wherein the oligonucleotide is a hybrid oligonucleotide.

5 3. The method of claim 1, wherein the oligonucleotide has a nucleotide sequence consisting essentially of the nucleotide sequence set forth in SEQ ID NO:4.

10 4. The method of claim 1, wherein the second agent is an antibody that binds to EGFR.

5. The method of claim 4, wherein the antibody is a monoclonal antibody.

15 6. The method of claim 5, wherein the antibody is C225.

20 7. The method of claim 1, wherein the second agent is a taxane.

8. The method of claim 7, wherein the taxane is selected from the group consisting of paclitaxel and docetaxel.

25 9. The method of claim 1, wherein the second agent is administered prior to administration of the first agent.

30 10. The method of claim 1, wherein the cancer cells are human cancer cells.

11. The method of claim 10, wherein the human cancer cells are selected from the group

consisting of breast cancer cells, colon cancer cells, and ovarian cancer cells.

12. A pharmaceutical composition comprising

5 (a) a first agent comprising a synthetic, modified oligonucleotide complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI α , the modified oligonucleotide having from
10 about 15 to about 30 nucleotides and being a hybrid, inverted hybrid, or inverted chimeric oligonucleotide,

the hybrid oligonucleotide comprising a region of at least two deoxyribonucleotides, flanked by 3' and 5' flanking ribonucleotide regions each having at least four ribonucleotides,

15 the inverted hybrid oligonucleotide comprising a region of at least four ribonucleotides flanked by 3' and 5' flanking deoxyribonucleotide regions of at least two deoxyribonucleotides,

20 and the inverted chimeric oligonucleotide comprising an oligonucleotide nonionic region of at least four nucleotides flanked by two oligonucleotide phosphorothioate regions; and

25 (b) a second agent comprising an antibody that binds to epidermal growth factor receptor (EGFR) or a cytotoxic agent selected from the group consisting of taxanes, platinum-derived agents, and topoisomeraseII-selective drugs.
30

13. The method of claim 12, wherein the oligonucleotide is a hybrid oligonucleotide.

14. The method of claim 12, wherein the oligonucleotide has a nucleotide sequence consisting essentially of the nucleotide sequence set forth in SEQ ID NO:4.

5

15. The method of claim 12, wherein the second agent is an antibody that binds to EGFR.

16. The method of claim 15, wherein the antibody is a monoclonal antibody.

10

17. The method of claim 12, wherein the antibody is C225.

18. The method of claim 12, wherein the second agent is a taxane.

15

19. The method of claim 18, wherein the taxane is selected from the group consisting of paclitaxel and docetaxel.

20

20. The method of claim 12, wherein the second agent is administered prior to administration of the first agent.

25

21. The method of claim 12, wherein the cancer cells are human cancer cells.

22. The method of claim 21, wherein the human cancer cells are selected from the group consisting of breast cancer cells, colon cancer cells, and ovarian cancer cells.

30

23. A method for treating cancer in an afflicted subject comprising

(a) administering to the cells a first agent comprising a synthetic, modified oligonucleotide complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RI α , the modified oligonucleotide having from about 15 to about 30 nucleotides and being a hybrid, inverted hybrid, or inverted chimeric oligonucleotide,

the hybrid oligonucleotide comprising a region of at least two deoxyribonucleotides, flanked by 3' and 5' flanking ribonucleotide regions each having at least four ribonucleotides,

the inverted hybrid oligonucleotide comprising a region of at least four ribonucleotides flanked by 3' and 5' flanking deoxyribonucleotide regions of at least two deoxyribonucleotides,

and the inverted chimeric oligonucleotide comprising an oligonucleotide nonionic region of at least four nucleotides flanked by two oligonucleotide phosphorothioate regions; and

(b) administering to the cells a second agent comprising an antibody that binds to epidermal growth factor receptor (EGFR) or a cytotoxic agent selected from the group consisting of taxanes, platinum-derived agents, and topoisomeraseII-selective drugs;

wherein the administering steps may be performed simultaneously or sequentially in any order.

24. The method of claim 23, wherein the oligonucleotide is a hybrid oligonucleotide.

5 25. The method of claim 24, wherein the oligonucleotide has a nucleotide sequence consisting essentially of the nucleotide sequence set forth in SEQ ID NO:4.

10 26. The method of claim 23, wherein the second agent is an antibody that binds to EGFR.

27. The method of claim 26, wherein the antibody is a monoclonal antibody.

15 28. The method of claim 27, wherein the antibody is C225.

20 29. The method of claim 23, wherein the second agent is a taxane.

30 30. The method of claim 29, wherein the taxane is selected from the group consisting of paclitaxel and docetaxel.

25 31. The method of claim 23, wherein the second agent is administered prior to administration of the first agent.

30 32. The method of claim 23, wherein the cancer cells are human cancer cells.

33. The method of claim 32, wherein the human cancer cells are selected from the group

consisting of breast cancer cells, colon cancer cells, and ovarian cancer cells.

ABSTRACT OF THE INVENTION

Disclosed are synthetic, modified
oligonucleotides complementary to, and capable of
5 down-regulating the expression of, nucleic acid
encoding protein kinase A subunit RI_α. The
modified oligonucleotides have from about 15 to
about 30 nucleotides and are hybrid, inverted
hybrid, or inverted chimeric oligonucleotides.
10 Also disclosed are therapeutic compositions
containing such oligonucleotides and methods of
using the same. In addition, therapeutic
compositions and methods of their use are
described which are directed to a synergistic
15 effect resulting from the combination of
oligonucleotides of the invention and other
therapeutic compositions and methods.

665001-24821700




FIG. 1




FIG. 2




FIG. 3

GEO




FIG. 4

Effect of HYB165 and its control HYB508
on A19, PTX10 and PTX22 ovarian carcinoma cell growth




FIG. 5

Effect of HYB165 and its control HYB508
on A19, PTX10 and PTX22 ovarian carcinoma cell growth




FIG. 6

Effect of HYB165 and its control HYB508
on A19, PTX10 and PTX22 ovarian carcinoma cell growth




FIG. 7




FIG. 8

Effect of HYB165 or HYB618 on
OVCAR-3 ovarian carcinoma cell growth




FIG. 9

ZR-75-1




FIG. 10

ZR-75-1




FIG. 11




FIG. 12

ZR-75.1 breast carcinoma




FIG. 13

**Effect of HYB165 or HYB508
on ZR-75.1 breast carcinoma cell growth**




FIG. 14

EFFECT OF HYB165 AND CONTROL HYB295 ON SOFT AGAR GROWTH
OF GEO COLON CANCER CELLS




FIG. 15

FIGURE 16A




FIGURE 16B




FIGURE 17A




FIGURE 17B




FIGURE 18

Table. Histochemical analysis of GEO tumors following treatment with taxol and/or different oral MBOs.

	Tumor size (cm ³)	Ki67	RI α	AR	TGF α	p27	Vessels
Control	1.49	40%	70%	85%	50%	10%	15
Taxol	0.80	20%	60%	70%	50%	10%	5
HYBI65	1.02	28%	35%	50%	20%	15%	3
Scramble	1.39	30%	60%	85%	50%	8%	14
HYBI65 + Taxol	0.4	6%	15%	25%	30%	25%	0
Scramble + Taxol	0.81	28%	60%	70%	50%	8%	7

Analysis was performed after the 2nd cycle of treatment (on day 27). Numbers represent the percentage of positive cell staining for each antigen.

DECLARATION AND POWER OF ATTORNEY
(Attorney Docket No: Hyz-050CP2)

As below-named inventors, I hereby declare that:

My residence, post office addresses and citizenship are as stated below next to my name.

I believe that I am the original, and only, inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES
AND METHODS OF THEIR USE**

the specification of which (check only one):

☒ [X] is attached hereto.

☐ [] was filed as United States Patent Application
Serial No. _____ on _____ and was amended on _____
(if applicable)

☐ [] was filed as PCT Patent Application Serial No. _____ on _____
and was amended under PCT Article 19 on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the claims of this application in accordance with Title 37, CFR §1.56(a) and §1.56(b). I also acknowledge the duty to disclose all information which is material to the patentability as defined in 37 CFR §1.56, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(e) or 365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS
UNDER 35 U.S.C. §119(a)-(d) or 365(b), or 365(a):**

COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED UNDER 35 U.S.C. §119 (YES/NO)

I hereby claim benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/103,098	10/05/1998	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or 365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATION OR PCT INTERNATIONAL APPLICATION(S)
DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120 or 365(c):**

APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS: (PATENTED, PENDING OR ABANDONED)
08/532,979	22/09/95	Pending
09/022,965	12/02/98	Pending

POWER OF ATTORNEY: As named inventors, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Scott M. Alter	Reg. No. 32,879
Hollie L. Baker	Reg. No. 31,321
Barbara A. Barakat	Reg. No. 32,190
Michael J. Bevilacqua	Reg. No. 31,091
Sally Byrne	Reg. No. 40,545
Nancy Chiu, Ph.D.	Reg. No. 43,545
Peter Dichiaro	Reg. No. 38,005
Michael A. Diener	Reg. No. 31,122
Richard Goldenberg	Reg. No. 38,895
Edward D. Grieff	Reg. No. 38,898

Wayne M. Kennard Reg. No. 30,271
Wayne A. Keown, Ph.D. Reg. No. 33,923
Ann-Louise Kerner, Ph.D. Reg. No. 33,523
Janice M. Klunder, Ph.D. Reg. No. 41,121
James B. Lampert Reg. No. 24,564
Ayla A. Lari Reg. No. 40,739
Keum J. Park Reg. No. 42,059
Jason A. Reyes Reg. No. 41,513
Gretchen Rice, Ph.D. Reg. No. 37,429
Donald R. Steinberg Reg. No. 37,241
Colleen Superko Reg. No. 39,850
Rajesh Vallabh Reg. No. 37,761
Henry N. Wixon Reg. No. 32,073

the mailing address and telephone number of each of whom is c/o HALE AND DORR LLP, 60 State Street, Boston, Massachusetts 02109, (617) 526-6000.

Send Correspondence to:

Ann-Louise Kerner, Ph.D.
HALE AND DORR LLP
60 State Street
Boston, Massachusetts 02109

Direct Telephone Calls to:

Ann-Louise Kerner, Ph.D.
(617) 526-6000 Phone
(617) 526-5000 Facsimile

Wherefore, I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole inventor: Sudhir Agrawal

Inventor's signature _____ Date _____
Residence: 61 Lamplighter Drive, Shrewsbury, MA 01545
Citizenship: India

kerner/hyz/050cp2/appln/decl_poa.wpf